REVMAN_ID,REVIEW_TITLE,PERFBIAS_RISK,PERFBIAS_JUDGEMENT,YEAR
STD-Akhondzadeh-2008,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Identical appearing tablets were used[comma] effectiveness of this method was not mentioned.,2008
STD-Buchanan-2008,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2008
STD-Caroff-2007,Acetylcholinesterase inhibitors for schizophrenia,Unclear Risk,No information available.,2007
STD-Chouinard-2007,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2007
STD-Dyer-2008,Acetylcholinesterase inhibitors for schizophrenia,Unclear Risk,No information available.,2008
STD-Fagerlund-2007,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2007
STD-Freudenreich-2005,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Identical appearing tablets were used[comma] effectiveness of this method was not mentioned.,2005
STD-Friedman-2002c,Acetylcholinesterase inhibitors for schizophrenia,Unclear Risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2002
STD-Keefe-2008a,Acetylcholinesterase inhibitors for schizophrenia,Unclear Risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2008
STD-Kim-2005b,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2005
STD-Kohler-2007,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2007
STD-Lee-2005,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2005
STD-Nahas-2003,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2003
STD-Schubert-2006,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2006
STD-Sharma-2006,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2006
STD-Tugal-2003,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2003
STD-Tuma-2003,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2003
STD-acupoint-cat---Sun-2005,Acupuncture for schizophrenia,High risk,Not used sham acupoint catgut treatment.,2005
STD-acupoint-cat---Wang-1997,Acupuncture for schizophrenia,Unclear Risk,Not used; sham acupoint catgut treatment.,1997
STD-acupoint-inj---Pan-2002,Acupuncture for schizophrenia,High risk,Sham acupoint injection not used.,2002
STD-acupoint-inj---Wang-2000,Acupuncture for schizophrenia,High risk,Sham acupoint injection not used.,2000
STD-acupoint-inj---Yang-2000,Acupuncture for schizophrenia,High risk,Sham acupoint injection not used.,2000
STD-EACT---Xue-1987,Acupuncture for schizophrenia,High risk,Author compared two groups and used electrodes with different positions.,1987
STD-electro---Chen-2006,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2006
STD-electro---Chen-2008,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2008
STD-electro---Cheng-2009,Acupuncture for schizophrenia,Low risk,Report stated - "blinded to the treatment allocation"; the acupuncturist was "instructed not to communicate with the patients and the clinical investigators"; the participants were "acupuncture-naive patients" and "there was also limited contact between the study participants and restricted conversation between acupuncturist and participants during treatment".,2009
STD-electro---Cui-2000,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2000
STD-electro---Ding-2005,Acupuncture for schizophrenia,High risk,Not used sham electroacupuncture and doctors often told patients (electroacupuncture + antipsychotics group) the importance and treatment mechanism of acupuncture.,2005
STD-electro---Wang-2005,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2005
STD-electro---Xiong-2010,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2010
STD-electro---Yao-2006,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2006
STD-electro---Zhang-1987,Acupuncture for schizophrenia,High risk,Sham electroacupuncture or any other dummy treatments not used.,1987
STD-electro---Zhang-1993,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,1993
STD-electro---Zhang-2001,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2001
STD-electro---Zhou-1997,Acupuncture for schizophrenia,High risk,Author compared two groups and did not use sham electroacupuncture.,1997
STD-laser---Liu-1986,Acupuncture for schizophrenia,High risk,Author reported that three groups all used laser irradiation (two real and one sham) and one group combined with chlorpromazine but did not reported the other two groups used dummy drug.,1986
STD-laser---Ma-1999,Acupuncture for schizophrenia,Unclear Risk,Sham laser irradiation not used.,1999
STD-laser---Zhang-1991,Acupuncture for schizophrenia,High risk,Though author compared 3 groups and used sham laser acupuncture did not use dummy medications.,1991
STD-traditional---Bouhlel-2011,Acupuncture for schizophrenia,Low risk,Reports stated - "double-blind". The author reported that both the patient and the psychiatrist did not know if it was a true traditional acupuncture treatment or a placebo (sham acupuncture).,2011
STD-traditional---Liu-2010,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2010
STD-traditional---Luo-2006,Acupuncture for schizophrenia,Unclear Risk,Report stated - "using single-blind method". No further details.,2006
STD-traditional---Ma-2008,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2008
STD-traditional---Tang-2005,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2005
STD-traditional---Wang-2006,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2006
STD-traditional---Xu-2004,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2004
STD-traditional---Zhao-2005a,Acupuncture for schizophrenia,High risk,Used placebo but did not use sham acupuncture.,2005
STD-traditional---Zhao-2005b,Acupuncture for schizophrenia,High risk,Used placebo but did not use sham acupuncture.,2005
STD-Henderson-2004-a,Advance treatment directives for people with severe mental illness,Low risk,One investigator collected follow-up data and was blinded to treatment group. Double-blinding not possible due to nature of intervention.,2004
STD-Papageorgiou-2002,Advance treatment directives for people with severe mental illness,High risk,"It was impossible to mask the research assistants to the patients' allocation as they were required to assist patients to make a directive in those allocated to the intervention group. However[comma] systematic bias was unlikely as the primary outcome concerned compulsory hospital admission and was not based on any later assessment by the researcher." Bias possible for secondary outcome measures.,2002
STD-Boyer-1995,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1995
STD-Carrière-2000,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Colonna-2000,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Costa-e-Silva-1989,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1989
STD-Danion-1999,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1999
STD-Delcker-1990,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1990
STD-Klein-1985,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1985
STD-Loo-1997,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Möller-1997,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Paillère-Martinot-95,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1995
STD-Peuskens-1999,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1999
STD-Pichot-1988a,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1988
STD-Pichot-1988b,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1988
STD-Puech-1998,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1998
STD-Rüther-1988,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1988
STD-Saletu-1994,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1994
STD-Speller-1997,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Wetzel-1998,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1998
STD-Ziegler-1989,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1989
STD-Bai-2005,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Single[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2005
STD-Hwang-2003,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules. Whether blinding was successful has not been examined[comma] but both compounds differ in side effects. This may be a problem for blinding.,2003
STD-Lecrubier-2006,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2006
STD-Mortimer-2004,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules ("to permit dose adjustment whilst maintaining the double-blind[comma] blister packs corresponding to a low and a high dosage were provided"). Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2005
STD-Möller-2005,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ in side effects. This may be a problem for blinding.,2004
STD-Olie-2006,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2006
STD-Peuskens-1999,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules. Whether blinding was successful has not been examined[comma] but both compounds in side effects. This may be a problem for blinding.,1999
STD-Sechter-2002,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ in side effects. This may be a problem for blinding.,2002
STD-Vanelle-2006,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2006
STD-Wagner-2005,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2005
STD-Mathew-1989,Amphetamines for schizophrenia,Information could not be retrieved,Information could not be retrieved,1989
STD-Modell-1965,Amphetamines for schizophrenia,Information could not be retrieved,Information could not be retrieved,1965
STD-Wolkin-1987,Amphetamines for schizophrenia,Information could not be retrieved,Information could not be retrieved,1987
STD-Wolkin-1994,Amphetamines for schizophrenia,Information could not be retrieved,Information could not be retrieved,1994
STD-Bucci-1971,Anticholinergic medication for antipsychotic-induced tardive dyskinesia,High risk,Blinding of participants and personnel not reported.,1971
STD-Greil-1984,Anticholinergic medication for antipsychotic-induced tardive dyskinesia,Low risk,"double-blind" "investigators were not informed about the study design".,1984
STD-Becker-1983,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1983
STD-Dufresne-1988,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1988
STD-Hogarty-1995,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1995
STD-Jasovic-1996,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1996
STD-Johnson-1981,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1981
STD-Kramer-1989,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1989
STD-Kurland-1981,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1981
STD-Mulholland-1997,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1997
STD-Prusoff-1979,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1979
STD-Singh-1978,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1978
STD-Siris-1987,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1987
STD-Collins-1967,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,1967
STD-Hayashi-1997,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Jockers-2005,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-Silver-1992,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,1992
STD-Spina-1994,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,1994
STD-Belanoff-2001,Antiglucocorticoid and related treatments for psychosis,Low risk,"..patients served as their own controls in a random-assignment[comma] double-blind crossover design" (pg 517).,2001
STD-DeBattista-2006,Antiglucocorticoid and related treatments for psychosis,Low risk,Quote: "randomised 1:1 to 7 days of inpatient treatment in a double-blind[comma] placebo controlled[comma] parallel group design" (pg 1344).,2006
STD-Flores-2006,Antiglucocorticoid and related treatments for psychosis,Low risk,Quote: "Patients were randomised to either 600mg per day of double-blind mifepristone or placebo for eight days" (pg 630).,2006
STD-Gallagher-2005,Antiglucocorticoid and related treatments for psychosis,Low risk,"Administration of medication was in a double-blind design" (pg 156). Outcome assessors were blind (source: correspondence).,2005
STD-Marco-2002,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: Yes. Quote: "Subjects were randomised to receive in a double-blind manner..." (pg 157). Outcome assessors: Yes. Quote: "Subjects and blinded raters were not able to accurately guess treatment assignment based on side effects." (pg 159).,2002
STD-Nachshoni-2005,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: Yes. Quote: "...randomised to receive either DHEA at a fixed dose of 100 mg/day or placebo in double-blind fashion..." (pg 252). Outcome assessors blind (from correspondence).,2005
STD-Newcomer-1998,Antiglucocorticoid and related treatments for psychosis,Low risk,Quote: "...after 4 days of double-blind[comma] placebo controlled treatment with DEX..." (pg 67).,1998
STD-Ritsner-2006,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: participants[comma] providers and key study personnel blinded (source: correspondence). Outcome assessors: yes (from correspondence).,2006
STD-Ritsner-2010,Antiglucocorticoid and related treatments for psychosis,Low risk,"Double-blind study design" (pg 1352).,2010
STD-Strous-2003,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: yes. Quote: "..to receive either DHEA or placebo[comma] each for six weeks in a double-blind manner (administered and monitored by a hospital pharmacist)" (pg 134). Outcome assessors blinded (Source: correspondence).,2003
STD-Strous-2007,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: Yes. Quote: "...to receive either DHEA or placebo[comma] each for 12 weeks in a double-blind manner" (pg 97). Outcome assessors blinded (source: correspondence).,2007
STD-Adler-1993a,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,1993
STD-Adler-1999,Antioxidant treatments for schizophrenia,Low risk,Double-blind[comma] no further details.,1999
STD-Akhondzadeh-2005,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2005
STD-Amiri-2008,Antioxidant treatments for schizophrenia,Low risk,Identical tablets.,2008
STD-Berk-2008b,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2008
STD-Bodkin-2005,Antioxidant treatments for schizophrenia,Low risk,"drug and placebo in matched capsules".,2005
STD-Bordbar-2008,Antioxidant treatments for schizophrenia,Low risk,"Identical placebo".,2008
STD-Brunstein-2005,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2005
STD-Dakhale-2005,Antioxidant treatments for schizophrenia,Low risk,Medicines identical in formulation.,2005
STD-Dickerson-2009,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2009
STD-Dorevitch-1997a,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,1997
STD-Doruk-2008,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2008
STD-Farokhnia-2013,Antioxidant treatments for schizophrenia,Low risk,"identical containers".,2013
STD-Goff-1993,Antioxidant treatments for schizophrenia,Low risk,Identical capsules given.,1993
STD-Jungerman-1999,Antioxidant treatments for schizophrenia,Low risk,"Identical appearance".,1999
STD-Lohr-1996,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,1996
STD-Luo-1997,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,1997
STD-Ritsner-2010,Antioxidant treatments for schizophrenia,Low risk,"identical capsules".,2010
STD-Weiser-2012,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2012
STD-Zhang-2001a,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2001
STD-Zhang-2004,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2004
STD-Zhang-2011,Antioxidant treatments for schizophrenia,Low risk,"Identically appearing placebo".,2011
STD-A-+any-antipsychotic-2011,Antipsychotic combinations for schizophrenia,High risk,Open-label[comma] participants and personnel were not blinded[comma] Assessment by blinded clinical raters[comma] precautions were taken not to reveal treatment allocation to raters.,2011
STD-A-+any-antipsychotic-2012,Antipsychotic combinations for schizophrenia,High risk,“Choice of medication to join was left to prescriber and patient  and also at their discretion the dose of all drug could be raised or lowered .” “Outcomes were performed by trained assessor masked to allocated treatment.”.,2012
STD-A-+any-antipsychotic-2015,Antipsychotic combinations for schizophrenia,High risk,“While treatment was open-label[comma] baseline and subsequent assessments were conducted by “independent assessors” blinded to the research status of participants.”.,2015
STD-A-+pimozide-1985,Antipsychotic combinations for schizophrenia,Low risk,Drug appearance[comma] with respect to powder colour[comma] taste[comma] and volume[comma] was made identical by adding a common gastric aid[comma] SMP.,1985
STD-A-+reserpine-1957,Antipsychotic combinations for schizophrenia,Low risk,Neither raters nor participants were aware of the nature or quantity of drug given. Participants were given an identical number of capsules regardless of the individual dosage.,1957
STD-A-+sulpiride-1994,Antipsychotic combinations for schizophrenia,High risk,Open-label study.,1994
STD-A-+trifluoperazine-1964,Antipsychotic combinations for schizophrenia,Low risk,Placebo capsules and placebo tablets matched the appearance of the capsules and tablets of the two drugs to insure no knowledge of which group was receiving which drug or drugs.,1964
STD-B-+any-antipsychotic-2013,Antipsychotic combinations for schizophrenia,High risk,“For participants who were assigned to switch to monotherapy[comma] each participant and physician decided together which of the two anti- psychotics to discontinue.”   “The raters were blinded about which group the patients belonged to.”.,2013
STD-B-+aripiprazole-2008,Antipsychotic combinations for schizophrenia,Unclear Risk,"Double-blind"[comma] no further details reported.,2008
STD-B-+aripiprazole-2011,Antipsychotic combinations for schizophrenia,Low risk,Aripiprazole and placebo were dispensed in identical-appearing capsules; patients randomise to placebo took the same number of capsules as those assigned to aripiprazole.,2011
STD-B-+pipotiazine-2002,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2002
STD-B-+quet/risp-2009,Antipsychotic combinations for schizophrenia,Unclear Risk,No details provided.,2009
STD-B-+risperidone-2010,Antipsychotic combinations for schizophrenia,Unclear Risk,"Double-blind"[comma] no further details provided for blinding of participants and personnel[comma] raters were blinded to treatment assignment.,2010
STD-B-+sulpiride-1996,Antipsychotic combinations for schizophrenia,Unclear Risk,Not described. Unclear if outcome assessment was blinded.,1996
STD-B-+ziprasidone-2014,Antipsychotic combinations for schizophrenia,Unclear Risk,“None of the research personnel[comma] who enrolled[comma] assessed[comma] and treated the patients[comma] were aware of the patient assignments until the study was concluded. Ziprasidone and placebo were dispensed in identical-appearing capsules; patients randomized to placebo took the same number of capsules as those assigned to ziprasidone.”.,2014
STD-C-+amisulpride-2008,Antipsychotic combinations for schizophrenia,Unclear Risk,No details provided.,2008
STD-C-+arip/pali-2014,Antipsychotic combinations for schizophrenia,Low risk,“Double blinding was done by inserting aripiprazole or paliperidone or placebo tablet in a non-transparent capsule.” “It was handed over along with identical plastic containers filled with the study drugs (45 capsules each of aripiprazole or paliperidone or placebo) to a third person not directly involved in this study.” “The patient as well as the investigator was unaware of the treatment being administered.”.,2014
STD-C-+aripiprazole-2007,Antipsychotic combinations for schizophrenia,Unclear Risk,Not reported.,2007
STD-C-+aripiprazole-2007b,Antipsychotic combinations for schizophrenia,Unclear Risk,No details provided.,2007
STD-C-+aripiprazole-2008,Antipsychotic combinations for schizophrenia,Low risk,All the participants and investigators remained blind throughout the study[comma] and the data analyses were also performed by investigators blind to the identity of the participants.,2008
STD-C-+aripiprazole-2008b,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2008
STD-C-+aripiprazole-2009,Antipsychotic combinations for schizophrenia,Unclear Risk,Single-blind[comma] untested.,2009
STD-C-+aripiprazole-2012,Antipsychotic combinations for schizophrenia,Unclear Risk,"Patients were evaluated by the same investigator. This investigator was from a different hospital and was not involved in patient care. In addition[comma] the investigator was blind to drug regimens and the drug concentrations. However[comma] he had access to the nursing charts." No details as to blindness of participants and personnel other than "double-blind".,2012
STD-C-+aripiprazole-2013,Antipsychotic combinations for schizophrenia,Unclear Risk,“Double blind” No other information provided.,2013
STD-C-+aripiprazole-2013b,Antipsychotic combinations for schizophrenia,Unclear Risk,“Double-blind”. No further details.,2013
STD-C-+aripiprazole-2014,Antipsychotic combinations for schizophrenia,Low risk,Double blind. Placebo[comma] which have the same colour[comma] shape and taste with aripiprazole.,2014
STD-C-+aripiprazole-2015,Antipsychotic combinations for schizophrenia,Low risk,"Double-blind”  "Placebo and aripiprazole tablets were physically indistinguishable.",2015
STD-C-+aripiprazole-2015b,Antipsychotic combinations for schizophrenia,Low risk,“placebo tablets that were identical to the aripiprazole tablets...” AND “The investigators[comma] participants and their carers were masked to the medications throughout the study...”.,2015
STD-C-+aripiprazole-2015c,Antipsychotic combinations for schizophrenia,High risk,“Open-label trial”.,2015
STD-C-+aripiprazole-2016,Antipsychotic combinations for schizophrenia,High risk,Open-label trial.,2014
STD-C-+clozapine-2001,Antipsychotic combinations for schizophrenia,Unclear Risk,No information provided.,2001
STD-C-+clozapine-2013,Antipsychotic combinations for schizophrenia,High risk,Not specified.,2013
STD-C-+CPZ-1973,Antipsychotic combinations for schizophrenia,Unclear Risk,At both centres[comma] all patients involved in the study had their dosage regulated by the usual clinical staff. The research psychiatrist at each centre scrupulously avoided influencing the amount or frequency of administration of antipsychotic medication used during the course of the study[comma] except to specify that fluphenazine enanthate dosage should not exceed 75 mg in a single dose.,1973
STD-C-+CPZ-1989,Antipsychotic combinations for schizophrenia,Unclear Risk,Weekly BPRS by psychiatrists blind to medication over 8 weeks. No further details.,1989
STD-C-+CPZ-1999,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,1999
STD-C-+fluphen-dec-2009,Antipsychotic combinations for schizophrenia,Low risk,"Double-blind". "The placebo had been arranged in the shape of comparable vials[comma] like the target drug". "The evaluators[comma] as well[comma] were unaware concerning the partition and the type of medications arranged for each group.",2009
STD-C-+haloperidol-2006,Antipsychotic combinations for schizophrenia,Unclear Risk,"Double-blind" no further details reported.,2006
STD-C-+haloperidol-2010,Antipsychotic combinations for schizophrenia,Unclear Risk,Double-blind[comma] no further details.,2010
STD-C-+levomepromazine 2004,Antipsychotic combinations for schizophrenia,High risk,Open-label trial.,2004
STD-C-+olan/risp-2014,Antipsychotic combinations for schizophrenia,High risk,Rater-blinded. Participants where not blinded to the intervention.,2014
STD-C-+olanzapine-2012,Antipsychotic combinations for schizophrenia,High risk,Participants and personnel were not blinded. Blind outcome assessment "Rater blinded".,2012
STD-C-+olanzapine-2012b,Antipsychotic combinations for schizophrenia,Low risk,Double blind: “Olanzapine and placebo were dispensed in similar gelatin capsules that were formulated for this trial.” “The rater was blind to the study medication (i.e.[comma] either olanzapine or placebo) until the completion of the trial in each case.”.,2012
STD-C-+perphenazine-1976,Antipsychotic combinations for schizophrenia,Low risk,Identical tablets were used for active drugs and placebo.,1976
STD-C-+pimozide-2011,Antipsychotic combinations for schizophrenia,Unclear Risk,Double-blind[comma] "Given that the increased risk of extrapyramidal symptoms associated with pimozide threatened the integrity of the blind[comma] assignment of assessments ensured that the rating of the ESRS was carried out by personnel different from those performing the PANSS and functional competence ratings.",2011
STD-C-+pimozide-2013,Antipsychotic combinations for schizophrenia,Low risk,Double-blind: “Patients were randomized to identical looking pimozide or placebo capsules by the research pharmacist who was not involved with the subjects.”.,2006
STD-C-+pipotiazine-2000,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2000
STD-C-+risperidone-2001,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2001
STD-C-+risperidone-2001b,Antipsychotic combinations for schizophrenia,Unclear Risk,No information provided.,2001
STD-C-+risperidone-2001c,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2001
STD-C-+risperidone-2005,Antipsychotic combinations for schizophrenia,Low risk,Identical pills containing either risperidone or placebo were added to clozapine.,2005
STD-C-+risperidone-2005b,Antipsychotic combinations for schizophrenia,Low risk,The raters[comma] treating psychiatrist[comma] and patient remained blinded throughout the study.,2005
STD-C-+risperidone-2006,Antipsychotic combinations for schizophrenia,Low risk,Throughout the study[comma] the patients[comma] sight investigators[comma] and raters remained blinded.,2006
STD-C-+risperidone 2007,Antipsychotic combinations for schizophrenia,Low risk,An independent research pharmacy prepared matching capsules that contained either 1 mg risperidone or placebo.,2007
STD-C-+sertindole-2006,Antipsychotic combinations for schizophrenia,Low risk,Participants[comma] personnel and assessors were blinded[comma] "Blinding was concealed until the end of the 12-week visit[comma] and disclosure of the blinding was first done after reporting all PANSS values to the pharmacy to ensure that the primary outcome data could not be changed after unblinding". Blinded raters performed all clinical research assessments.,2006
STD-C-+sulpiride-1997,Antipsychotic combinations for schizophrenia,Low risk,The placebo tablets were made to appear identical to the sulpiride tablets by the manufacturer.,1997
STD-C-+sulpiride-1999,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,1999
STD-C-+sulpiride-1999b,Antipsychotic combinations for schizophrenia,Unclear Risk,Double-blind.,1999
STD-C-+sulpiride-1999c,Antipsychotic combinations for schizophrenia,Unclear Risk,No information provided.,1999
STD-C-+sulpiride-2003,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2003
STD-C-+sulpiride-2004,Antipsychotic combinations for schizophrenia,High risk,Limitations for the study include the absence of a double-blind[comma] placebo-controlled study design[comma] and non-blind rating.,2004
STD-C-+sulpiride-2006,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2006
STD-C-+sulpiride-2013,Antipsychotic combinations for schizophrenia,Unclear Risk,“Double blind”. No other information provided.,2013
STD-Huang-2007,Antipsychotic drug treatment for elderly people with late-onset schizophrenia,High risk,There was no blinding.,2007
STD-Engelhardt-1973,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,1973
STD-Faretra-1970,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,1970
STD-Kumra-1996,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,1996
STD-Shaw-2006,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,2006
STD-Xiong-2004,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,2004
STD-Yao-2003,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Cole-1964,Antipsychotic medication for early episode schizophrenia,Unclear Risk,Double blind[comma] untested.,1964
STD-May-1976,Antipsychotic medication for early episode schizophrenia,High risk,Open study.,1965
STD-Mosher-1995,Antipsychotic medication for early episode schizophrenia,High risk,Treated at different sites.,1995
STD-Rappaport-1978,Antipsychotic medication for early episode schizophrenia,Low risk,Reported that "staff remain blind to whether the patient was receiving medication or placebo".,1978
STD-Simon-1965,Antipsychotic medication for early episode schizophrenia,Unclear Risk,No details.,1959
STD-Harvey/Jeste-2003,Antipsychotic medication for elderly people with schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Phanjoo-1990,Antipsychotic medication for elderly people with schizophrenia,Information could not be retrieved,Information could not be retrieved,1990
STD-Tollefson-1997,Antipsychotic medication for elderly people with schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Bai-2003,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Low risk,"double-blind" "A placebo with an identical appearance to the risperidone dose was prescribed for the placebo group using the same dose schedule.",2003
STD-Bai-2005,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,"single-blind and controlled study".,2005
STD-Caroff-2011,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Low risk,"...double-blind conditions..." "Identical-appearing capsules contained olanzapine (7.5 mg)[comma] quetiapine (200 mg)[comma] risperidone (1.5 mg)[comma] perphenazine (8 mg)[comma] or ziprasidone (40 mg).",2011
STD-Chan-2010,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,"...primary care physicians and patients were not blinded.",2010
STD-Chouinard-1995,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Low risk,"identical tablets".,1995
STD-Cookson-1987,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Unclear Risk,"double blind"[comma] no further details.,1987
STD-Emsley-2004,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,"investigator-blinded"[comma] further blinding details not reported.,2004
STD-Glazer-1990a,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Low risk,"double blind" "Medication was supplied in identical-appearing red capsules containing 25 mg and 5 mg[comma] respectively[comma] of molindone and haloperidol".,1990
STD-Kane-1983,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Unclear Risk,"double-blind". Details not reported.,1983
STD-Kazamatsuri-1972,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Unclear Risk,Blinding of participants not reported. Ward nurses were blinded.,1972
STD-Kazamatsuri-1973,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,Blinding of participants and personnel not reported.,1973
STD-Lublin-1991,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,Blinding of participants and personnel not reported.,1991
STD-Tamminga-1994,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Unclear Risk,"Staff[comma] patients[comma] and all raters were blind to the drug group; one non rating physician and one nurse were non blind to dispense medication and monitor safety"; no further details were provided.,1994
STD-Casey-2003,Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems,Low risk,Quote: "Open label".  Comment: lack of blinding is less prone to cause bias for outcomes like weight. Lack of blinding may introduce bias for subjective outcomes like adverse events.,2003
STD-Cookson-1986,Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems,Low risk,Quote:" double blind"  Comment: the methods used if any to ensure participants and trialists were blind to the interventions used are not described. We feel as the primary outcome is objective (weight) inadequate blinding is unlikely to cause bias.,1986
STD-Eli-Lilly-2004,Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems,Low risk,Quote: "double blind". Comment: the methods used if any to ensure participants and trialists were blind to the interventions used are not reported[comma] but both the intervention medication and the control were in capsule forms. We feel inadequate blinding is not likely to introduce bias for objective outcomes like weight BMI and metabolic syndrome.,2004
STD-Newcomer-2008,Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems,Low risk,Quote:"double blind study". Comment: methods taken to ensure blindness not reported. For outcomes like weight[comma] BMI[comma] waist circumference and metabolic syndrome[comma] inadequate blinding is unlikely to cause bias.,2007
STD-Andrezina-2006,Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation),Unclear Risk,Described as double-blind[comma] no further details given.,2006
STD-Bristol-Myers-2005,Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation),Unclear Risk,No blinding was used during the preparation of injections; in most cases the same person prepared and administered the drug. Study investigators conducting the assessment were blinded to treatment.,2005
STD-Kittipeerachon-2016,Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation),Low risk,"The patients and the physician investigator were blinded to treatment assignment as long as the 24-hour assessment was not completed. The assessment was performed by the investigator and the nurse who administered the injection was not involved in the assessment process of the study." (p.232).,2016
STD-Adson-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Carson-2000-a,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Carson-2002-b,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2002
STD-Csernansky-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Daniel-2000,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Daniel-2004,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2004
STD-Kane-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Kern-2001,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2001
STD-Kujawa-2002,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2002
STD-Marcus-2005,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-McQuade-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Oren-2005,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-Potkin-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Riera-2004,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2004
STD-Stock-2005,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-An-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Bai-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Unclear.,2007
STD-Bai-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ban-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Chan-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.,2007
STD-Chang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Chen-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Chen-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Chen-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Chen-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2009
STD-Chen-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Chen-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Low riskUnclear riskHigh risk.,2010
STD-Chen-2010a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Cheng-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-CuiMeng-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Dai-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Dai-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Deng-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Deng-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Ding-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Du-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Fan-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Fan-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Feng-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Fleischhacker-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.,2005
STD-Fu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ge-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ge-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Guo-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double.,2006
STD-Han-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Han-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Han-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Hu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Huang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ji-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Jiang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Jie-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Kane-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,No details.,2009
STD-Kern-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2006
STD-Kerwin-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2007
STD-Kinon-2004,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double. No further details available.,2004
STD-Kuang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006[comma] 2006
STD-Li-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Li-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Li-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Li-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Li-2007b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Li-2007c,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Li-2007d,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Li-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Li-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Li-2009b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Li-X-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Lian-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liang-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Liu-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Liu-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Liu-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008c,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008d,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Liu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Liu-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Liu-2009b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Liu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Lou-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Luo-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Luo-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Lv-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Ma-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ma-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Mai-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Mao-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-McQuade-2004,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.,2004
STD-Mu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Mu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Pan-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Peng-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Peng-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Potkin-2003,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.,2003
STD-Pu-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Qian-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Qin-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Qu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Shan-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Shuai-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Song-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Song-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Song-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Su-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Su-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Sun-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Sun-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Sun-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Tandon-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2006
STD-Tang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Tang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Tang-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Tang-2010a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Tao-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Tong-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Tu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wang-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Wang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2006b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2006c,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2006d,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wang-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wang-2007d,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wang-2007e,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wang-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Wang-2008c,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Wang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wei-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Wei-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wei-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wen-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wen-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wlodzmierz-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2006
STD-Wolf-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2007
STD-Wu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Xiao-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Xie-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Xie-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Xu-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Xu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Low risk,Double.,2010
STD-Yan-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double.,2007
STD-Yan-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yan-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yan-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Yang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not stated.,2006
STD-Yang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Yang-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yang-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yang-2008b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ye-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Ye-2005a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Yi-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Yu-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Yu-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Yu-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Yu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Yu-ZG-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Zhang-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Zhang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhang-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhang-2007b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhang-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhang-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhang-2008b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Zhang-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Single[comma] if the blinding was performed well was unknown.,2009
STD-Zhang-2009b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Zhang-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Zhang-2010a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Zhao-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not described.,2006
STD-Zhao-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhi-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Zhou-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhou-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhou-2007b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhou-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhu-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Single blind[comma] but whether the blindness was performed well was unclear.,2005
STD-Zhu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Zimbroff-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Low risk,Double[comma] double dummy administration. Whether blinding was successful has not been examined[comma] but both compounds have similar adverse effects.,2007
STD-Zou-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Adson-2003,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double blind[comma] no further details.,2003
STD-Carson-2000-a,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double blind[comma] method of blinding not described.,2000
STD-Carson-2002-b,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2002
STD-Csernansky-2003,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2003
STD-Daniel-2000,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Unclear.,2000
STD-Daniel-2004,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2004
STD-Marcus-2005,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2005
STD-Oren-2005,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2005
STD-Potkin-2003,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2003
STD-Carson-2000,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Csernansky-2003,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Daniel-2000,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Daniel-2004,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2004
STD-Kane-2003,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Kujawa-2002,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2002
STD-McCue-2006,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2006
STD-Oren-2005,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-Wang-2005,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-Green-1987,Art therapy for schizophrenia or schizophrenia-like illnesses,Information could not be retrieved,Information could not be retrieved,1987
STD-Richardson-2002,Art therapy for schizophrenia or schizophrenia-like illnesses,Information could not be retrieved,Information could not be retrieved,2000
STD-Chapel-2009,Asenapine versus placebo for schizophrenia,Unclear Risk,"Double-blind" - but no further description provided.,2009
STD-Kane-2010,Asenapine versus placebo for schizophrenia,Unclear Risk,"Double-blind" - but no further description provided.,2010
STD-Kane-2011,Asenapine versus placebo for schizophrenia,Low risk,"Double-blind". "asenapine and placebo sublingual tablets were identical in appearance". "neither patients nor sites were aware of the tablet identity". Probably done.,2011
STD-NCT00151424,Asenapine versus placebo for schizophrenia,Unclear Risk,Double-blind - no further description.,2005
STD-NCT00156117,Asenapine versus placebo for schizophrenia,Unclear Risk,"Double-Blind (subject[comma] caregiver[comma] investigator[comma] outcomes assessor)". No further description.,2005
STD-Potkin-2007,Asenapine versus placebo for schizophrenia,Low risk,"Double-blind" "In this double-dummy design[comma] asenapine-treated patients also received oral placebo BID...and patients in the placebo-control group received oral and sublingual placebo BID". Probably done.,2007
STD-Alfredsson-1984,Atypical antipsychotics for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1984
STD-Emsley-2003,Atypical antipsychotics for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,2003
STD-Jasovic-1997,Atypical antipsychotics for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1997
STD-Aranda-2007,Atypical antipsychotics for psychosis in adolescents,High risk,This was an open-label study.,2007
STD-DelBello-2008,Atypical antipsychotics for psychosis in adolescents,High risk,This was an open-label trial.,2006
STD-Findling-2008,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind placebo-controlled trial.,2008
STD-Haas-2009,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind study.,2009
STD-Huo-2007,Atypical antipsychotics for psychosis in adolescents,Unclear Risk,Not described in the report.,2007
STD-Jensen-2008,Atypical antipsychotics for psychosis in adolescents,High risk,This was an open-label study.,2007
STD-Kryzhanovskaya-2009,Atypical antipsychotics for psychosis in adolescents,Low risk,There was a double-blind phase followed by an open-label phase.,2009
STD-Kumra-1996,Atypical antipsychotics for psychosis in adolescents,Low risk,Raters[comma] treating physicians and nurses were blind to the study status.,1996
STD-Kumra-2008,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind RCT[comma] but the details of blinding and how it was maintained had not been described in the report.,2008
STD-Sikich-2004,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind study[comma] but the details of how blinding was maintained were not reported.,2004
STD-Sikich-2008,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind study[comma] and blinding was maintained even after discontinuation of one of the arms (olanzapine group) of the study for ethical reasons.,2008
STD-Swadi-2010,Atypical antipsychotics for psychosis in adolescents,High risk,Open-label study with blind midpoint and end point assessments.,2010
STD-Xiong-2004,Atypical antipsychotics for psychosis in adolescents,High risk,Blinding not clear.,2004
STD-Mahal-1976,Ayurvedic medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1976
STD-Ramu-1992,Ayurvedic medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1992
STD-Ramu-1999,Ayurvedic medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1999
STD-Eckmann-1984,Benperidol for schizophrenia,Unclear Risk,Quote: "double-blind study". Oral liquid medication. No further details.,1984
STD-Bobruff-1981,Benzodiazepines for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double-blind". Details not reported.,1981
STD-Csernansky-1988,Benzodiazepines for antipsychotic-induced tardive dyskinesia,Low risk,"Patients were randomly assigned to the treatment with either alprozalam[comma] diadepam[comma] or placebo under double-blind conditions. Identical capsules contained either 1 mg of alprozalam[comma] 10mg of diazepam[comma] or the drug carrier as placebo.",1988
STD-Weber-1983,Benzodiazepines for antipsychotic-induced tardive dyskinesia,High risk,As one of the groups received an intervention and the second standard care[comma] blinding of participants and personnel could not have been possible.,1983
STD-Xiang-1997,Benzodiazepines for antipsychotic-induced tardive dyskinesia,Low risk,"double blind." "The two drugs were contained in capsules with same appearance." Blinding of participants and key study personnel ensured.,1997
STD-Kutcher-1989,Benzodiazepines for neuroleptic-induced acute akathisia,Information could not be retrieved,Information could not be retrieved,1989
STD-Pujalte-1994,Benzodiazepines for neuroleptic-induced acute akathisia,Information could not be retrieved,Information could not be retrieved,1994
STD-Alprazolam-1992[comma]-USA,Benzodiazepines for psychosis-induced aggression or agitation,Low risk,Double-blind - the investigators who administered the scales were blind to each other's ratings[comma] and trial author DMM was blind to the dose and schedule of treatment. Both investigators were blind to drug assignment. Rating scales: trial author JGB administered the BPRS-psychosis subscale[comma] SANS[comma] SAPS and trial author DMM administered the full-scale version of the BPRS - ratings were not a self-report or completed by an independent rater.,1992
STD-Clonazepam-1993[comma]-CA,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Double blind - the evaluating psychiatrist was "blind to treatment allocations" and determined the exact dose of medication. The haloperidol group also received procyclidine with each dose - to maintain double-blind conditions[comma] the clonazepam group received procyclidine placebo with each dose. Rating scales: > 80% completed by a study psychiatrist[comma] it was unclear whether the rater was blinded.,1993
STD-Clonazepam-1999[comma]-CHN,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Not stated. Rating scales: unclear who administered the rating scales.,1999
STD-Clonazepam-2007a[comma]-CHN,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Double blind[comma] not state who was blinded.,2007
STD-Diazepam-1979[comma]-IL,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Observer blind - it is unclear how trial authors remained blinded to alternation and decrease of haloperidol dosage. Rating scales: BPRS and CGI were performed by consensus of 2 physicians (trial authors EL and YL)[comma] who were "unaware of the treatment administered.",1979
STD-Flunitrazepam-1999[comma]-IL,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Not state whether investigators were blinded. Rating scales: trial coauthor administered rating scales used for study. All rating scales (OAS[comma] BPRS and CGI) were completed by author NK[comma] who was blind to the study medications; unclear whether dose adjustment was blind.,1999
STD-Lorazepam-1989[comma]-USA,Benzodiazepines for psychosis-induced aggression or agitation,High risk,Non-blind[comma] authors stated[comma] "we considered that the degree of tranquillisation desired when treating agitated patients is easily ascertained[comma] and thus we did not use control subjects and a blind design." Rating scales: unclear who administered rating scales used to determine baseline agitation ratings.,1989
STD-Lorazepam-1991[comma]-USA,Benzodiazepines for psychosis-induced aggression or agitation,Low risk,Investigators were likely to have been blinded as the parenteral medication was prepared in advance by a member of the research staff who had no direct clinical responsibility for the participant. Rating scales: raters were blind to the treatment condition received by the participant. OAS ratings were obtained by staff nurses. BPRS ratings were obtained by "trained study psychiatrists." Adverse effects and sedation were assessed by clinicians who did not participate in evaluating therapeutic results.,1991
STD-Lorazepam-1997a[comma]-USA,Benzodiazepines for psychosis-induced aggression or agitation,Low risk,Double-blind - "the emergency department psychiatrist who treated and rated the patient remained blinded to the identity of the patient's medication throughout treatment." Rating scales: administered by emergency department psychiatrist[comma] who also treated the participant[comma] but "remained blinded to the identity of the patient's medication throughout.",1997
STD-Lorazepam-1997b[comma]-USA,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Double blind; however[comma] no further description of blinding provided. Rating scales: symptom ratings were conducted by 1 of 4 raters (psychiatry residents or psychiatric nursing staff). Raters were trained by trial author SF.,1997
STD-Lorazepam-1998[comma]-SA,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Medications administered using "double blind procedures." Not stated who was blinded. Rating scales were completed by 1 of 4 people who were "trained" by study author (SF).,1998
STD-Lorazepam-1998[comma]-USA,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Double blind - "a member of nursing staff[comma] independent of patient assessment or treatment[comma] prepared and coded each injection of equal volume." Rating scales: administered by an investigator - unclear whether this investigator was an independent rater.,1998
STD-Lorazepam-2001[comma]-RO-and-USA,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Double blind - no further description. Rating scales: Agitation-Calmness Evaluation Scale - single-item 9-point scale[comma] developed by trial sponsors Eli Lilly and Company (results not included). Unclear who administered the rating scales used.,2001
STD-Lorazepam-2004[comma]-IN,Benzodiazepines for psychosis-induced aggression or agitation,High risk,Investigators not blinded[comma] as blinding was kept until point of treatment assignment[comma] which minimised selection bias. Rating scales: study co-ordinators[comma] who were blind to interventions given[comma] undertook ratings.,2004
STD-Lorazepam-2006[comma]-USA,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Double blind - no further description. Rating scales: administered by trained study evaluators[comma] with inter-rater reliability assessed by independent evaluation of a video-taped mode.,2006
STD-Lorazepam-2009[comma]-SK,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Not stated.,2009
STD-Lorazepam-2010[comma]-IN,Benzodiazepines for psychosis-induced aggression or agitation,High risk,Open label.,2010
STD-Midazolam-2003[comma]-BZ,Benzodiazepines for psychosis-induced aggression or agitation,High risk,Investigators were not blinded as the blinding was kept until point of treatment assignment[comma] which minimised selection bias. Doses of medication administered were "at the treating doctors discretion." Rating scales: raters were nurses/doctors not involved in the management of the emergency - unknown to treating clinicians.,2003
STD-Midazolam-2006[comma]-AU,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Double blind; blinding was maintained by returning sealed envelopes contained in study pack. It is stated[comma] however[comma] that "if necessary for patient treatment[comma] unblinding of the drug could be achieved by opening [the sealed envelope];" unclear whether this was done. A blinded explicit review of the participant's medical record was performed after discharge. 2 participants from each treatment group (n = 4) were treated on an 'unblinded' basis - no further details are given. Rating scale: not stated who administered rating scales.,2006
STD-Midazolam-2011[comma]-BZ,Benzodiazepines for psychosis-induced aggression or agitation,Unclear Risk,Double blind - study medications were packaged in identical colour-coded boxes. Rating scales were repeatedly administered by 2 raters - unclear whether these were independent raters.,2011
STD-Azima-1962,Benzodiazepines for schizophrenia,Low risk,“Multi-blind”; “identical placebos”.,1962
STD-Barbee-1992,Benzodiazepines for schizophrenia,Low risk,“Double-blind”; “identically appearing placebo tablet”.,1992
STD-Battaglia-1997,Benzodiazepines for schizophrenia,Low risk,"Double-blind". "The emergency department psychiatrist who treated and rated the patient remained blinded to the identity of the patient’s medication throughout treatment." The non-blinding of others is unlikely to introduce bias. The "syringes containing the study drug were prepared by a non-blinded nurse or hospital pharmacist and delivered to the emergency department as needed.",1997
STD-Carpenter-1999,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind”; no further details.,1999
STD-Cheung-1981,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind”; no further details.,1981
STD-Chouinard-1993,Benzodiazepines for schizophrenia,Low risk,“Double-blind”. “To ensure double-blind conditions[comma] the clonazepam group received procyclidine placebo with each dose.” The nurse administering the drugs i.m. injections “was not blind to the treatment allocations”[comma] but this was unlikely to introduce bias.,1993
STD-Dorevitch-1999,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind“; no further details.,1999
STD-Foster-1997,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind”; no further details.,1997
STD-Garza-Trevino-1989,Benzodiazepines for schizophrenia,High risk,Non-blind.,1989
STD-Gundlach-1966,Benzodiazepines for schizophrenia,Low risk,“Double-blind”. “Placebo was matched in appearance.” “The psychiatrists[comma] social workers and other personnel dealing with the patients did not have access the code indicating which patients were treated with diazepam and which with placebo.”.,1966
STD-Guz-1972,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind”[comma] no further details.,1972
STD-Hankoff-1962,Benzodiazepines for schizophrenia,Low risk,“Double-blind”; “All the drugs and their placebos were administered in pink No. 2 capsules.”.,1962
STD-Hanlon-1969,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind”[comma] no further details.,1969
STD-Hanlon-1970,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind”[comma] no further details.,1970
STD-Holden-1968,Benzodiazepines for schizophrenia,Low risk,“Double-blind”. “The drugs were prepared in identical capsules.” Comment: Probably done.,1968
STD-Kurland-1966,Benzodiazepines for schizophrenia,Low risk,“Double-blind”; “Chlordiazepoxide[comma] imipramine[comma] and placebo were dispensed from the pharmacy in identical opaque white capsules[comma] so that neither patients nor research personnel knew which of theses medications was being administered.” Comment: Probably done.,1966
STD-Kutcher-1989,Benzodiazepines for schizophrenia,Low risk,“Double blind”; tablets were “identical in appearance” Comment: Probably done.,1989
STD-Lerner-1979,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind”; no further details.,1979
STD-Lingjaerde-1979,Benzodiazepines for schizophrenia,Low risk,“Double-blind”. “Tablets of identical appearance.” Comment: Probably done.,1979
STD-Lingjaerde-1982,Benzodiazepines for schizophrenia,Low risk,“Double-blind”. “Similar-looking placebo tablets” Comment: Probably done.,1982
STD-Ma-2006,Benzodiazepines for schizophrenia,Unclear Risk,Single-blind; no further details.,2006
STD-Marneros-1979,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind”[comma] no further details.,1979
STD-Merlis-1962,Benzodiazepines for schizophrenia,Low risk,“Double-blind”. “Capsules of identical appearance[comma] identified on the ward only by code letter.” Comment: Probably done.,1962
STD-Minervini-1990,Benzodiazepines for schizophrenia,Low risk,“Alpidem tablets of 50 mg and placebo tablets were identical in size and appearance.” Comment: Probably done.,1990
STD-Morphy-1986,Benzodiazepines for schizophrenia,Unclear Risk,“Double-blind”; no further details.,1986
STD-Nestoros-1982,Benzodiazepines for schizophrenia,Low risk,“Double-blind”; “matched tablets”. Comment: Probably done.,1982
STD-Nishikawa-1982,Benzodiazepines for schizophrenia,Low risk,“Double-blind”. “Drug appearance[comma] with respect to powder colour[comma] taste and volume[comma] was made identical by adding a kind of stomachics.” Comment: Probably done.,1982
STD-Pujalte-1994,Benzodiazepines for schizophrenia,Low risk,“Double-blind”; “identical appearance” of the study medication. Comment: Probably done.,1994
STD-Stevens-1992,Benzodiazepines for schizophrenia,High risk,“The study design was open.”.,1992
STD-TREC-Rio-2003,Benzodiazepines for schizophrenia,High risk,“Open treatment.”.,2003
STD-Wang-2000,Benzodiazepines for schizophrenia,High risk,Non-blind.,2000
STD-Wang-2003,Benzodiazepines for schizophrenia,High risk,Not double-blind; no further details.,2003
STD-Wyant-1990,Benzodiazepines for schizophrenia,Unclear Risk,“Single-blind”; no further details.,1990
STD-Xuan-2007,Benzodiazepines for schizophrenia,High risk,Non-blind; no further details.,2007
STD-Allan-1996,Beta-blocker supplementation of standard drug treatment for schizophrenia,Low risk,Double-blind[comma] no details.,1996
STD-Alpert-1990,Beta-blocker supplementation of standard drug treatment for schizophrenia,Low risk,Double blind[comma] no details.,1990
STD-Karniol-1982,Beta-blocker supplementation of standard drug treatment for schizophrenia,Low risk,Double blind[comma] no details.,1982
STD-Myers-1981,Beta-blocker supplementation of standard drug treatment for schizophrenia,Low risk,Double blind[comma] no details.,1981
STD-Poyurovsky-2006,Beta-blocker supplementation of standard drug treatment for schizophrenia,Low risk,Double blind[comma] explained.,2006
STD-Pugh-1983,Beta-blocker supplementation of standard drug treatment for schizophrenia,Low risk,Double blind[comma] no details.,1983
STD-Ratey-1992,Beta-blocker supplementation of standard drug treatment for schizophrenia,Low risk,Double blinded[comma] no details.,1992
STD-Wells-1991,Beta-blocker supplementation of standard drug treatment for schizophrenia,Low risk,No details.,1991
STD-Yorkston-1977,Beta-blocker supplementation of standard drug treatment for schizophrenia,Unclear Risk,Blinding implied[comma] but no details.,1976
STD-Barbato-2006,Bifeprunox versus placebo for schizophrenia,Unclear Risk,"Double-blind" no further details reported.,2006
STD-Bourin-2007,Bifeprunox versus placebo for schizophrenia,Unclear Risk,"Double-blind" no further information reported.,2007
STD-Casey-2007,Bifeprunox versus placebo for schizophrenia,Unclear Risk,"Double-blind" no further details reported.,2007
STD-Meltzer-2007,Bifeprunox versus placebo for schizophrenia,Unclear Risk,"Double-blind" no further information reported.,2007
STD-McLaren-1992,Bromperidol decanoate (depot) for schizophrenia,Unclear Risk,Quote: "Bromperidol decanoate or fluphenazine decanoate in identical ampoules". Unclear if raters independent and unclear if blinding was successful.,1992
STD-Rossi-1990,Bromperidol decanoate (depot) for schizophrenia,Unclear Risk,Investigator involved in selection and outcome evaluation[comma] did not access randomisation list and drug administration.,1990
STD-Rossi-1992,Bromperidol decanoate (depot) for schizophrenia,Unclear Risk,Quote: "Drugs were provided in identical packages in order to maintain double-blindness".,1992
STD-Smeraldi-1990,Bromperidol decanoate (depot) for schizophrenia,Unclear Risk,Quote: "The placebo and bromperidol phials were perfectly identical".,1990
STD-Loonen-1992,Calcium channel blockers for antipsychotic-induced tardive dyskinesia,Low risk,"double-blind to placebo tablets which looked identically;" "The double-blind code was not broken until the last patient had terminated.",1992
STD-Schwartz-1997,Calcium channel blockers for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double-blind;" further details were not reported.,1997
STD-Zeng-1994,Calcium channel blockers for antipsychotic-induced tardive dyskinesia,Low risk,"double blind study[comma] the interventions were coded as intervention A or B by the researcher in pharmacy;" "Participants and personnel did not know the allocation result. The two drugs contained in capsules with the same appearance." Blinding of participants and key study personnel ensured.,1994
STD-Akerele-2007,Cannabis and schizophrenia,Unclear Risk,Risperidone and olanzapine in gelatin capsules containing riboflavin - unclear if successful - not tested.,2007
STD-Bonsack-2011,Cannabis and schizophrenia,Low risk,Assessments by independent parties[comma] participants blind.,2011
STD-Brunette-2011,Cannabis and schizophrenia,High risk,Clinicians and participants not blinded.,2011
STD-Edwards-2006,Cannabis and schizophrenia,Low risk,Quote: 'A single-blind randomised controlled trial.',2006
STD-Hjorthoj-2013,Cannabis and schizophrenia,High risk,Fourteen patients or managers accidentally broke the blinding.,2013
STD-Leweke-2012,Cannabis and schizophrenia,Low risk,Prepared by person uninvolved in study.,2012
STD-Madigan-2012,Cannabis and schizophrenia,Low risk,Single blind (uninvolved researcher responsible for randomisation).,2012
STD-van-Nimwegen-2008,Cannabis and schizophrenia,Low risk,Double blind.,2006
STD-Carpenter-1991,Carbamazepine for schizophrenia,Unclear Risk,"Double-blind"[comma] "identical placebo tablets" (p.69)[comma] "number of carbamazepine tablets was adjusted by a nonblind psychiatrist" (p.70).,1991
STD-Dose-1987,Carbamazepine for schizophrenia,Unclear Risk,"Double-blind" - no further details (p.304).,1987
STD-Heßlinger-1998,Carbamazepine for schizophrenia,Unclear Risk,"Psychiatrist (...) was blind to medication and drug levels. However[comma] he had access to the nursing charts" (p.311) Patients were not aware of the treatment (information received by letter).,1998
STD-Llorca-1993,Carbamazepine for schizophrenia,Low risk,"Tout au long de l'étude[comma] les patients sont à l'insu du traitement recu. Durant les 4 phase de l'expérimentation[comma] patients et investigateurs sont à l'insu de la médication adjuvante recue". "Afin de maintenir les conditions de double aveugle[comma] les résultats des dosages pratiqués sont collectés au fur et à mesure de l'étude par un médecin différent du cotateur (M.A.W.)" "capsules identiques".,1993
STD-Mair-1990,Carbamazepine for schizophrenia,Unclear Risk,Blinding not described (an open study) (p.79).,1990
STD-Martin-Munoz-1989,Carbamazepine for schizophrenia,Unclear Risk,"Doble ciego"[comma] no further details.,1989
STD-Nachshoni-1994,Carbamazepine for schizophrenia,Low risk,"Double-blind design" (p.24)[comma] patients and personal were blind[comma] tablets were identical (letter).,1994
STD-Neppe-1983,Carbamazepine for schizophrenia,Unclear Risk,"Double blind" (p.326).,1983
STD-Simhandl-1996,Carbamazepine for schizophrenia,Unclear Risk,"Double-blind"[comma] no further details.,1996
STD-Svestka-1989,Carbamazepine for schizophrenia,Unclear Risk,No information available.,1989
STD-Adler-1989,Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia,Information could not be retrieved,Information could not be retrieved,1989
STD-Irwin-1988,Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia,Information could not be retrieved,Information could not be retrieved,1988
STD-Kramer-1988,Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia,Information could not be retrieved,Information could not be retrieved,1988
STD-Andrews-1976,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1976
STD-Caffey-1964,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1963
STD-Freeman-1962,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1962
STD-Greenberg-1966,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1966
STD-Hogarty-1973-a,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1973
STD-Mathur-1981,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1981
STD-Morton-1968,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1968
STD-Pigache-1973,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1973
STD-Shawver-1959,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1959
STD-Zeller-1956,Cessation of medication for people with schizophrenia already stable on chlorpromazine,Information could not be retrieved,Information could not be retrieved,1956
STD-Chen-1997,Chinese herbal medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Luo-1997-a,Chinese herbal medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Meng-1996,Chinese herbal medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1996
STD-Zhang-1987,Chinese herbal medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1987
STD-Zhang-1997,Chinese herbal medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Zhang-2001,Chinese herbal medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,2001
STD-Zhu-1996,Chinese herbal medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1996
STD-Chouinard-1976,Chlorpromazine dose for people with schizophrenia,Low risk,Quote: "double-blind conditions"[comma] "identical-appearing tablets...administered three times a day" pp119[comma] p6. Comment: probably done (double[comma] tablets of identical appearance[comma] same amount of tablets and treatment scheme to all patients).,1976
STD-Clark-1972,Chlorpromazine dose for people with schizophrenia,Low risk,Quote: "double-blind study" pp479[comma] p5; "all patients received the same volume of medication (10 mL twice daily) but in different concentration" pp262[comma] p1 Comment: probably done.,1972
STD-Prien-1968,Chlorpromazine dose for people with schizophrenia,Low risk,Quote: "The low dose and placebo group also received liquid concentrate[comma] on a double-blind basis" pp483[comma] p6. Comment: identical liquid administration. Blinding probably done.,1968
STD-Wode-Helgodt-1978,Chlorpromazine dose for people with schizophrenia,Low risk,Quote: “For drug administration the “double-dummy technique” was used[comma] i.e. every patient received the same total number of tablets containing CPZ or placebo. The appearance of the placebo tablets was identical to those containing CPZ” pp152[comma] p1. Comment: double-dummy technique probably done[comma] same tablet numbers and shape.,1978
STD-Xu-2009,Chlorpromazine dose for people with schizophrenia,Unclear Risk,Not mentioned. No detail information was described in the study.,2009
STD-Man-1973,Chlorpromazine for psychosis induced aggression or agitation,Unclear Risk,Quote: "conducted under double-blind conditions..."  not tested.,1973
STD-HGCQ-(Turkey)-2000,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,High risk,No blinding.,2000
STD-HGDV-(Morocco)-1999,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,High risk,No blinding. Quote: "This is an open label study...personnel at the study site[comma] patients and personnel at Lilly were not blinded as to the treatment being administered.",1999
STD-vs-OLZ---An-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2006
STD-vs-OLZ---Chang-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2003
STD-vs-OLZ---Chen-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2006
STD-vs-OLZ---He-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2003
STD-vs-OLZ---Loza-1999-(HGDT),Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,High risk,This is an open label study.,1999
STD-vs-OLZ---Luo-2007,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2007
STD-vs-OLZ---Wang-2002,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,High risk,Open label. Quote: "test and control drugs were administrated openly." p2665.,2002
STD-vs-OLZ---Wang-2008,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2008
STD-vs-OLZ---Wu-2008,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2008
STD-vs-OLZ---Zhao-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2006
STD-vs-QTP---Ai-2007,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2007
STD-vs-QTP---An-2005,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2005
STD-vs-QTP---Cai-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2006
STD-vs-QTP---Cai-2007,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2007
STD-vs-QTP---Cao-2005,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2005
STD-vs-QTP---Chen-2001,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2001
STD-vs-QTP---Chen-2007,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2007
STD-vs-QTP---Chen-2008,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2008
STD-vs-QTP---Cheng-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2003
STD-vs-QTP---Deng-2004,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2004
STD-vs-QTP---Guo-2003a,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2003
STD-vs-QTP---Guo-2003b,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2003
STD-vs-QTP---Guo-2005,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2005
STD-vs-QTP---Guo-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2006
STD-vs-QTP---Guo-2007,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2007
STD-vs-QTP---Guo-2008,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2008
STD-vs-QTP---He-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2003
STD-vs-QTP---Hu-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2003
STD-vs-QTP---Ji-2004,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2004
STD-vs-QTP---Jiang-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2006
STD-vs-QTP---Jiang-2008,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2008
STD-vs-QTP---Jin-2007,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2007
STD-vs-QTP---Kong-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2003
STD-vs-QTP---Li-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2003
STD-vs-QTP---Li-2010,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2010
STD-vs-QTP---Liu-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2003
STD-vs-QTP---Mei-2007,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2007
STD-vs-QTP---Nai-2007,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2007
STD-vs-QTP---NCT00882518,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2009
STD-vs-QTP---Peng-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Double blind[comma] but untested.,2006
STD-vs-QTP---Peuskens-1997,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,1997
STD-vs-QTP---Sun-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2006
STD-vs-QTP---Tian-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2006
STD-vs-QTP---Wan-2002,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2007
STD-vs-QTP---Wan-2008,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2008
STD-vs-QTP---Wang-2004,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2004
STD-vs-QTP---Wang-2005,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2005
STD-vs-QTP---Yang-2007,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2007
STD-vs-QTP---Zhang-2002,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2002
STD-vs-QTP---Zhang-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2003
STD-vs-QTP---Zhang-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2006
STD-vs-QTP---Zhang-2008,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2008
STD-vs-QTP---Zhou-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2003
STD-vs-QTP---Zhou-2004,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2004
STD-vs-QTP---Zou-2006,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2006
STD-vs-RPD---Chang-1998,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,1998
STD-vs-RPD---Cui-2001,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Low risk,Double blind (clinician and patients are blinded). Quote "risperidone and chlorpromazine were placed into capsules of equal size and same colour[comma] dispensed by pharmacist. Neither patients or clinician are aware of the content of the capsule." p206.,2001
STD-vs-RPD---Feng-2003,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Double-blind[comma] but untested.,2003
STD-vs-RPD---He-1999,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,1999
STD-vs-RPD---Lin-2005,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2005
STD-vs-RPD---Liu-2000,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2000
STD-vs-RPD---Liu-2005,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2005
STD-vs-RPD---Luo-2001,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Double blind[comma] but untested.,2001
STD-vs-RPD---Ma-2004,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2004
STD-vs-RPD---Wang-2002,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2002
STD-vs-RPD---Wang-2005,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2005
STD-vs-RPD---Wu-2002,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2002
STD-vs-RPD---Wu-2004,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not reported.,2004
STD-vs-RPD---Zheng-2001,Chlorpromazine versus atypical antipsychotic drugs for schizophrenia,Unclear Risk,Not stated.,2001
STD-Jacobsson-1974,Chlorpromazine versus clotiapine for schizophrenia,Low risk,Quote: "clotiapine or 100 mg chlorpromazine were administered using the double-blind technique".,1974
STD-Kaneko-1969,Chlorpromazine versus clotiapine for schizophrenia,Low risk,Quote: "Employed as the experimental method in the present study. was the double-blind[comma] controlled technique ".,1969
STD-Schliefer-2003,Chlorpromazine versus clotiapine for schizophrenia,Low risk,Quote: "The design was double-blind crossover".,2003
STD-Van-Wyk-1971,Chlorpromazine versus clotiapine for schizophrenia,High risk,Quote: "Because of the administrative and staff shortage problems we could not introduce· any 'blind' procedures into the trial".,1971
STD-Kramer-1975,Chlorpromazine versus metiapine for schizophrenia,Low risk,Quote: "a four-week double-blind study.",1975
STD-Simpson-1973,Chlorpromazine versus metiapine for schizophrenia,Low risk,Quote: "The study was conducted under double blind condition.",1973
STD-Steinbook-1975,Chlorpromazine versus metiapine for schizophrenia,Low risk,Quote: "in a double blind manner.",1975
STD-Chouinard-1977,Chlorpromazine versus penfluridol for schizophrenia,Unclear Risk,Described as double blind-no further details reported.,1977
STD-Claghorn-1979,Chlorpromazine versus penfluridol for schizophrenia,Unclear Risk,Described as "double blind"-placebo tablet given to penfluridol group to cover non-drug days. No further details reported.,1979
STD-Wang-1982,Chlorpromazine versus penfluridol for schizophrenia,Low risk,"All patients received identical appearing capsules on a special "blister pack" medi­cation card allowing the patient to take the medication on a twice-a-day schedule".,1982
STD-Abrams-1958,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"The experimental group received chlorpromazine under the name of "Thoraxine A"[comma] "The control group[comma] received a placebo[comma] the same size[comma] shape and colour as the chlorpromazine. As a differentiation from the chlorpromazine[comma] the placebo was known as "Thorazine B".,1958
STD-Baker-1959,Chlorpromazine versus placebo for schizophrenia,Low risk,"Matching tablets" were used.,1959
STD-Ban-1975,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "All medication was supplied in capsules identical in appearance[comma] taste and smell".,1975
STD-Bishop-1963,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"Double blind" no further details reported.,1963
STD-Borison-1991,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"Double blind" no further details reported.,1991
STD-Chouinard-1990,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double blind"[comma] "The trial drugs were provided in the form of identical white opaque gelatin capsules".,1990
STD-Clark-1961,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind"[comma] "neither the patients nor the personnel involved in the care or evaluation of the subjects were informed of any individual's medication until the end of the study. Medications were dispensed in individually labeled bottles so that identification by code was not possible".,1961
STD-Clark-1967,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind procedure in which neither the investigators nor the subjects knew who was receiving chlorpromazine. Medications were dispensed in identical-appearing capsules from individual stock bottle labeled only with the patient's name.",1967
STD-Clark-1968a,Chlorpromazine versus placebo for schizophrenia,Low risk,"Identically appearing capsules from each subject's individually labelled stock bottle to meet the double-blind requirements of the study".,1968
STD-Clark-1968b,Chlorpromazine versus placebo for schizophrenia,Low risk,Double-blind"[comma] "All medications were identical in appearance".,1968
STD-Clark-1970a,Chlorpromazine versus placebo for schizophrenia,Low risk,"Identically appearing capsules"[comma] "double-blind[comma] with medications dispensed from individual stock bottles labelled only with the patient's name".,1970
STD-Clark-1970b,Chlorpromazine versus placebo for schizophrenia,Unclear Risk, No information reported.,1970
STD-Clark-1971,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind"[comma] "identical appearing medication was administered from a bottle labelled only with the patient's name".,1971
STD-Clark-1972,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind"[comma] identical appearing medication in capsule form was administered orally to each subject rom his individual stock bottle labelled only with his name".,1972
STD-Clark-1977,Chlorpromazine versus placebo for schizophrenia,Low risk,"Placebo tablets identical to the white butaclamol and to the brown CPZ preparations were taken by all subjects during the dryout period and by the placebo group during treatment". "Each patient received his/her medication from individual stock bottles". "Double-blind".,1977
STD-Cohen-1968,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"Double-blind" no further details reported.,1968
STD-Cole-1964,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" oral medication "prepared as standard No. 2 pink capsules"[comma] IM from "1 cc glass ampules" with sterile saline for placebo.,1964
STD-Cooper-2000,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "A double-dummy technique was used to maintain blinding because of differences in capsule and tablet appearances[comma] i.e. patients received active zotepine plus placebo chlorpromazine or placebo zotepine plus active chlorpromazine or double placebo.",2000
STD-Dean-1958,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"Those patients on placebo were given tablets which were identical in appearance with chlorpromazine." "Until the patients were receiving 1000 mg of chlorpromazine a day[comma] the hospital pharmacist was was the only person who knew which patients were receiving placebos. At the 1000 mg level the ward physician checked the master list to determine who was on the placebos".,1958
STD-Engelhardt-1960,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "The medication was in the form of pink capsules containing either placebo[comma] promazine hydrochloride or chlorpromazine hydrochloride". "The treating psychiatrist did not know which agent the patient received".,1960
STD-Fink-1963,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "Each medication was dissolved in a highly flavoured liquid vehicle and each patient received 40ml per day from individually labelled bottles".,1963
STD-Fleming-1959,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "the tablets of the 3 treatments were identical in appearance[comma] the hospital dispenser alone knowing to which treatment any particular patient had been assigned at the outset".,1959
STD-Grygier-1958,Chlorpromazine versus placebo for schizophrenia,Unclear Risk, No information reported.,1958
STD-Gwynne-1962,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"All drugs and placebo were identical in appearance and taste." No further details reported.,1962
STD-Hall-1955,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "identical-appearing placebo".,1955
STD-Hamill-1975,Chlorpromazine versus placebo for schizophrenia,Unclear Risk, No information reported.,1975
STD-Hamilton-1960,Chlorpromazine versus placebo for schizophrenia,Low risk,"Form the point of view of the patients[comma] nurses and physicians[comma] there were 27 patients receiving one kind of tablet and 27 patients receiving the other kind[comma] but only the pharmacist knew which of the patients were receiving active and which inert tablets. All the tablets were sugar-coated nad the placebo tablets were indistinguishable from the active drugs. ".,1960
STD-Hankoff-1962,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "All the drugs and their placebos were administered in pink No.2 capsules".,1962
STD-Hine-1958,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"Double-blind" "The results of this assignment were not known to the judges[comma] raters or other ward personnel" "corresponding placebo tablets or solution" no further details reported.,1958
STD-Hogarty-1973,Chlorpromazine versus placebo for schizophrenia,Low risk,"Assigned on a double-blind basis to identical looking 100 mg or 50 mg tablets of chlorpromazine or placebo".,1973
STD-Klein-1973,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "Medication was administered in a highly flavoured liquid placebo[comma] and each patient received a constant 40 ml/day from individually labelled bottles".,1973
STD-Kurland-1961,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "The drugs were dispensed in standard unmarked capsules [...] coloured pink to mask all identifying consistencies and colours of the drugs".,1961
STD-Letemendia-1967,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "Neither patients[comma] doctors[comma] nor nurses knew which patients were being given chlorpromazine and which placebo. All medication was dispensed in uniform amber-coloured capsules. Each patient was supplied from a separated bottle[comma] replenished weekly according to the design by an independent party".,1967
STD-Nishikawa-1982,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "Drug appearance[comma] with respect to powder colour[comma] taste and volume[comma] was  made identical by adding a kind of stomachics.,1982
STD-Payne-1960,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "All three types of tablet were exactly the same colour[comma] size and shape. Each patient's medication was supplied to the wards in identical containers bearing the patient's name only. The physician and ward personnel were unaware of which patient was receiving which tablet; the latter being known only to the pharmacist and not divulged until the completion of the investigation".,1960
STD-Peet-1981,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "Capsules of identical appearance".,1981
STD-Prien-1968,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"Double-blind" no further details reported.,1968
STD-Ramu-1999,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "The medicines and placebo were administered in the form of identical tablets".,1999
STD-Ramu-1999a,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"Double-blind" "Sugar coated uniform tablets of the trial drugs" no further details reported.,1999
STD-Rappaport-1978,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"physician [...] and the nursing staff remained blind as to whether the patient was receiving medication or placebos" no further details reported.,1978
STD-Reardon-1966,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"Neither the ward personnel nor the investigator knew which drug the patient received" no further details reported.,1966
STD-Reschke-1974,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"Double-blind" no further details reported.,1974
STD-Saretsky-1966,Chlorpromazine versus placebo for schizophrenia,Low risk,"The drugs were packaged in individual bottles with only the patient's name printed on them as a means of identification." "Throughout the experiment[comma] whether the patient received the drug or a placebo was not known to anyone connected with the experiment." "The two kinds of pills were identical in size[comma] shape[comma] colour[comma] and taste.",1966
STD-Schiele-1961,Chlorpromazine versus placebo for schizophrenia,Low risk,"During the first 16 weeks[comma] the study was carried out under strict double-blind conditions. Each patient had his individual bottle of medication; the capsules were identical in appearance[comma] and only the hospital pharmacist had the code for determining which patient was receiving each kind of medication".,1961
STD-Serafetinides-1972,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"All medications were prepared in identically appearing capsules" no further details reported.,1972
STD-Shepherd-1956,Chlorpromazine versus placebo for schizophrenia,Low risk,Two kinds of inert substances were employed[comma] one indistinguishable from reserpine[comma] the other from chlorpromazine. Nobody but the ward doctor allocating the drugs and the dispenser knew which patients were receiving drugs and which patients were on placebo".,1956
STD-Simon-1958,Chlorpromazine versus placebo for schizophrenia,Unclear Risk, No information reported.,1958
STD-Smith-1961,Chlorpromazine versus placebo for schizophrenia,Low risk,"The medication used during the study was prepared in identical capsules" "Neither the patients nor the attending physicians knew what medication was being given. An identifying code was available but not broken until the end of the study.",1961
STD-Somerville-1960,Chlorpromazine versus placebo for schizophrenia,Low risk,"The two placebos were identical in appearance with the respective active tablets.",1960
STD-Spohn-1977,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"During the drug treatment period[comma] patients[comma] project personnel[comma] and hospital personnel were "blind" to the patients' drug status" no further details reported.,1977
STD-Tetreault-1969,Chlorpromazine versus placebo for schizophrenia,Low risk,"TPS-23 (50mg[comma] chlorpromazine (100 mg) and placebo presented in identical white capsules; they were distributed on the ward in containers on which only the patient's name appeared. The double-blind technique was followed throughout the experiment".,1969
STD-Vaughan-1955,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,"The hospital pharmacist alone knowing which patients were receiving chlorpromazine and which the placebo" no further details reported.,1955
STD-Walsh-1959,Chlorpromazine versus placebo for schizophrenia,Low risk,As this involved periodic changes in the number and/or size  of the tablets[comma] the number and/or size of the tablets given to the placebo group was altered simultaneously. Neither the doctor nor the ward staff were aware of the nature of the preparation being given to a particular patient. A separate bottle was assigned to each patient and in this supplies of the specific preparation were issued at weekly intervals".,1959
STD-Weckowicz-1960,Chlorpromazine versus placebo for schizophrenia,Low risk,"Double-blind" "The patients in the three groups received respectively from bottles marked "A"[comma] "B" and "C" 50mg tablets which looked exactly the same".,1960
STD-Xiong-1994,Chlorpromazine versus placebo for schizophrenia,Unclear Risk,Double blind.,1994
STD-Ayd-1956,Chlorpromazine versus reserpine for schizophrenia,Unclear Risk,No indication of blinding.,1956
STD-Barrett-1957,Chlorpromazine versus reserpine for schizophrenia,Low risk,Text in study: "parallel control group is used to insure that the raters remain objective in their ratings. If the raters are not aware of wether they are rating an experimental or a control subject[comma] they are more apt to base their ratings on observations than on personal bias". "The genuine surprise of the raters upon learning that there was actually no control group lent further support to the impression that the raters indeed behaved as though there was a control group" - blinding the raters. SN and CEA judgement: nice approach to remain as objective as possible considering many refined methods.,1957
STD-Gardner-1955,Chlorpromazine versus reserpine for schizophrenia,Low risk,Text in study: "The double blind method was employed[comma] except that the responsible ward physician prescribed the drugs because of the need for close observation for toxic effects" - no further details. SN and CEA judgement: in general the double-blind method was obtained[comma] so overall acceptable.,1955
STD-Kovitz-1955,Chlorpromazine versus reserpine for schizophrenia,Low risk,Text in study: "attendants[comma] nurses[comma] and physicians [...] did not know which medication their patients were receiving". SN and CEA judgement: blinding of personnel seems to work but no further details about the double-blind technique is given.,1955
STD-Kurland-1956,Chlorpromazine versus reserpine for schizophrenia,Unclear Risk,Not reported.,1956
STD-Lasky-1962,Chlorpromazine versus reserpine for schizophrenia,Low risk,Text in study: "Drugs were administered in capsules of identical appearance[comma] using double-blind controls". SN and CEA judgement: Based on the knowledge about double-blind both the participants and the personnel did not know about the drug the patient was receiving[comma] additionally the identical appearance is a sign for the employment of the double-blind method.,1962
STD-Shepherd-1956,Chlorpromazine versus reserpine for schizophrenia,Low risk,Text in study: "Two kinds of inert substances were employed[comma] one indistinguishable in appearance and taste from reserpine[comma] the other from chlorpromazine. Nobody but the ward doctor allocating the drugs and the dispenser knew which patients were receiving drugs and which patients were on placebo". SN and CEA judgement: might have distinguished between drugs because of adverse effects but both compound unfamiliar to doctors and patients of that time.,1956
STD-Wirt-1959,Chlorpromazine versus reserpine for schizophrenia,Low risk,Text in study: "the staff were kept ignorant of the order within the random list". "The particular group into which a patient would be placed was not known until after he had been selected as suitable for the study". SN and CEA judgement: clearly underlined that the staff were blinded.,1959
STD-Zeller-1956,Chlorpromazine versus reserpine for schizophrenia,Unclear Risk,Text in study:"Multiple[comma] independent clinical observations were made by members of a research team who were thoroughly familiar with the pattern of each patient's illness before drug or placebo treatment was instituted". SN and CEA judgement: since members of research team were aware of the clinical history of their patients before and after drug administration it is very likely that the blinding method was not employed at all.,1956
STD-Beckham-1981,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Low risk,"double blind". "Only a member of the hospital pharmacy staff was aware of each patient's group assignment during the study. The investigator[comma] patients[comma] ward nurses[comma] and physicians were all blind to patient status." "The control substance was a mixture of crushed graham cracker and corn oil which[comma] when mixed with milk[comma] resembled the lecithin mixture in taste[comma] appearance[comma] and viscosity. The mixtures were further disguised and made more palatable by the addition of artificial sweetener and vanilla extract.",1981
STD-Caroff-2007,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double-blind[comma]" details not reported.,2007
STD-de-Montigny-1979,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double-blind" Details not reported.,1979
STD-Gelenberg-1990,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double-blind". "Several lecithin preparations were used during the study. We started with frappes prepared with chunks of 55% PC. That preparation was succeeded by chunks[comma] chicken soup[comma] and granola bars that contained 80% to 100% PC. Placebo included corn oil in frappes[comma] ground corn flakes[comma] and matching chicken noodle soup and granola bars." Unclear if the lecithin and placebo preparations were identical (color[comma] taste[comma] smell...)."The 14 completers were asked to fill out a questionnaire in which they specified (l) which of the two medications they thought was most helpful[comma] (2) what effects (if any) they noted on their mood[comma] and (3) whether they could guess which of the two medications was lecithin and which was placebo. Seven of the 14 patients felt that one treatment was definitely more helpful than the other; of those[comma] 6 indicated that lecithin was the more helpful treatment.",1990
STD-George-1981,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double-blind"[comma] further details not reported.,1981
STD-Jackson-1978,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double-blind"[comma] details not reported.,1978
STD-Jackson-1979,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Low risk,"double-blind"; "Each dose of lecithin or placebo was prepared in a coded bottle independent of the patient clinical staff[comma] and raters". "No attempt was made to systematically and objectively rate body odour[comma] but no significant change[comma] and particularly no "fishy odour[comma]" was noted by the subjects[comma] ward staff[comma] or raters.",1979
STD-Jahanian-2014,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"Double blind". No details reported.,2014
STD-Kocher-1980,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double blind" not described.,1980
STD-Lucius-1976,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,Identical capsules planned[comma] but apparently differences in form and taste.,1976
STD-Ogunmefun-2009,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double-blind"[comma] no further details reported.,2009
STD-Price-1982,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Low risk,"double-blind". "Although the subjects assigned to one of the treatment groups were informed that they would receive either the lecithin treatment or a placebo control treatment[comma] neither the patients nor the researcher knew to which group any individual had been assigned." "The placebo substance resembled the lecithin mixture in taste[comma] .appearance[comma] and thickness" The no treatment group's participants could not have been blinded.,1982
STD-Tarsy-1977,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double blind" no details reported.,1977
STD-Yagi-1990,Cholinergic medication for antipsychotic-induced tardive dyskinesia,Unclear Risk,"double blind" not described.,1990
STD-Itoh-1969,Clotiapine for acute psychotic illnesses,Information could not be retrieved,Information could not be retrieved,1969
STD-Jacobsson-1974,Clotiapine for acute psychotic illnesses,Information could not be retrieved,Information could not be retrieved,1974
STD-Perales-1974,Clotiapine for acute psychotic illnesses,Information could not be retrieved,Information could not be retrieved,1974
STD-Subramaney-1998,Clotiapine for acute psychotic illnesses,Information could not be retrieved,Information could not be retrieved,1998
STD-Uys-1996,Clotiapine for acute psychotic illnesses,Information could not be retrieved,Information could not be retrieved,1996
STD-Cipriani-2013a,Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia,High risk,Quote: "...the patients and clinicians were not blind to pharmacological treatments.",2013
STD-Genç-2007,Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia,Unclear Risk,No information on blindness of participants given.,2007
STD-Kong-2001,Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia,Unclear Risk,Insufficient information.,2001
STD-Kuwilsky-2010,Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia,High risk,Quote: "open label"; "antipsychotics were applied in an open manner.",2009
STD-Wen-2015,Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia,Unclear Risk,Described as single blind.,2015
STD-Chen-1998,Clozapine dose for schizophrenia,High risk,Not stated.,1998
STD-Chen-2013,Clozapine dose for schizophrenia,High risk,Not stated.,2013
STD-Liu-2005,Clozapine dose for schizophrenia,High risk,Not stated.,2005
STD-Sheng-1990,Clozapine dose for schizophrenia,Unclear Risk,‘Double blind’[comma] no further details.,1990
STD-Simpson-1999,Clozapine dose for schizophrenia,Unclear Risk,Participants were blinded to doses of clozapine; no details on personnel giving the treatment.,1999
STD-Atmaca-2003,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: "raters were blind to drug assignment." "The prescribing physician was not blind to assignment" Comment: Single/rater blind study. Subjective measures may lead a source of bias. Also review authors believe that the fact the prescribing physician was not blind will introduce bias. The success of blinding was not evaluated.,2003
STD-Azorin-2001,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “..assigned to double-blind treatment”. Comment: Probably done. The success of blinding was not evaluated.,2001
STD-Bitter-2004,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “This was a Phase III[comma] 18-week[comma] randomised[comma] double blind[comma] parallel study” Comment: The success of blinding was not evaluated.,2004
STD-Bondolfi-1998,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “Double blind[comma] double dummy protocol” Comment: Probably done. The success of blinding was not evaluated.,1998
STD-Breier-1999,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: "..double blind comparison trial.” Comment: Probably done. The success of blinding was not evaluated.,1999
STD-Conley-2003,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: ”randomised double-blind 16 week..” Comment: Probably done. The success of blinding was not evaluated.,2003
STD-Heinrich-1994,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “This is a randomised[comma] double blind study..” Tablets were identical appearance. Comment: Probably done. The success of blinding was not evaluated.,1994
STD-Krakowski-2006,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “The medication was administered in a double-blind fashion..” The success of blinding was not evaluated. Comment: Probably done.,2006
STD-Kumra-2008,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “medication was administered under double-blind condition”. The success of blinding was not evaluated.,2008
STD-Li--2002,Clozapine versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] probably identical capsules. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side-effects. This can be a problem for blinding. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter[comma] probably leads a low risk of bias.,2002
STD-Li--2003,Clozapine versus other atypical antipsychotics for schizophrenia,Unclear Risk,Single[comma] rater-blind. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side-effects. This can be a problem for blinding. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter[comma] probably leads a low risk of bias.,2003
STD-Li--2005,Clozapine versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side-effects. This can be a problem for blinding. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter[comma] probably leads a low risk of bias.,2005
STD-Lin-2003,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: ".. patients were allocated on a random[comma] rater blind basis.." Probably done. The success of blinding was not evaluated.,2003
STD-Lindenberg-1997,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “They were randomly assigned in a double design to clozapine or zotepine” Comment: Probably done. The success of blinding was not evaluated.,1977
STD-Liu--2004,Clozapine versus other atypical antipsychotics for schizophrenia,Unclear Risk,Single[comma] rater-blind. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side-effects. This can be a problem for blinding. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter[comma] probably leads a low risk of bias.,2004
STD-McGurk-2005,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “ double-blind[comma] 29 week trial..” Comment: Probably done.,2005
STD-Meltzer-2003,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Single-open label/blind raters. Comment: Probably done. The rater’s masking was monitored by external service.,2003
STD-Moresco-2004,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote:“ A double blind[comma] parallel study.” Comment: Probably done. The success of blinding was not evaluated.,2004
STD-Naber-2005,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “This randomised double blind controlled trial..” Comment: Probably done. Identical capsules were used.The success of blinding was not evaluated.,2005
STD-Ren-2002,Clozapine versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but the compounds differ quite substantially in side-effects. This can be a problem for blinding. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter[comma] probably leads a low risk of bias.,2002
STD-Sacchetti-2006,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “Patients completed a 3-7 day screening period before being randomised[comma] double-blind..” Comment: Probably done. The success of blinding was not evaluated.,2006
STD-Shaw-2006,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Double blind. Identic tablet form. Quote: “Participants and those administering and assessing the intervention and assessing outcomes were blind..” “The success of the blinding was not formally assessed”.,2006
STD-Tollefson-2001,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “An 18-week double-blind therapy” Comment: Probably done. The success of blinding was not evaluated.,2001
STD-Volavka-2002,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Quote: “In a double blind trial..” “.. all tablets looked alike”. Comment: Probably done.,2002
STD-Wahlbeck-2000,Clozapine versus other atypical antipsychotics for schizophrenia,Low risk,Open label/assessor blinded study. Comment: probably done. The success of blinding was not evaluated.,2000
STD-Wang-2002,Clozapine versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side-effects. This can be a problem for blinding. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter[comma] probably leads a low risk of bias.,2002
STD-Zhou-2000,Clozapine versus other atypical antipsychotics for schizophrenia,Unclear Risk,Single[comma] rater-blind. Whether blinding was successful has not been examined[comma] but the compounds differ quite substantially in side-effects. This can be a problem for blinding. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter[comma] probably leads a low risk of bias.,2000
STD-Buchanan-1994-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1994
STD-Chiu-1976-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] identical capsules[comma] untested.,1976
STD-Ciurezu-1976-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1976
STD-Claghorn-1983-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1983
STD-Dong-1999-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,1999
STD-Du-2003-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Not reported.,8466
STD-Erlandsen-1977-(H),Clozapine versus typical neuroleptic medication for schizophrenia,High risk,Double blind[comma] but investigators were able to guess correctly in all patients after two to three days[comma] due to the sedating and relaxing effect of clozapine.,1977
STD-Essock-1996-(H/CPZ/Flu),Clozapine versus typical neuroleptic medication for schizophrenia,High risk,Open label.,1996
STD-Fan-1999-(Clopen),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Two raters did not conduct treatment.,1999
STD-Fischer-C-1974-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1974
STD-Fischer-C-1976-a-(Clopen),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] identical capsules[comma] untested.,1976
STD-Gelenberg-1979-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1979
STD-Gerlach-1974-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Participants aware of treatment; assessors were blind[comma] untested.,1974
STD-Gerlach-1975-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1975
STD-Guirguis-1977-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1977
STD-Guo-Zhen-2002-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,8389
STD-Hong-1997-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Single blinding[comma] both medications were identical in appearance and package but two raters were also researchers[comma] untested.,1997
STD-Honigfeld-1984-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1984
STD-Howanitz-1996-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1996
STD-Huang-2001-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,2001
STD-Itoh-1974-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] not tested.,1974
STD-Kane-1988-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested[comma] adverse effects (Table 7) clearly different making blinding problematic.,1988
STD-Kane-1995-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1996
STD-Klieser-1988-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1988
STD-Klieser-1990-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind mostly[comma] single blind for adverse events[comma] untested.,1990
STD-Kumra-1994-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double mostly but single for adverse events[comma] untested.,1994
STD-Lee-1994-(mainly-H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Single[comma] assessors blind to drug allocation[comma] untested.,1994
STD-Leon-1974-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double[comma] untested.,1974
STD-Li-2003-(Lox),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Not reported.,2003
STD-Lieberman-2003-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,2003
STD-Liu-1994-(Thi),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1994
STD-Liu-2002-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Not reported.,2002
STD-Liu-2004-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Not reported.,2004
STD-Niu-2001-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,2001
STD-Ou-1999-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,1999
STD-Potter-1989-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1989
STD-Rosenheck-1993-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1993
STD-Shopsin-1978-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] identical capsules[comma] untested.,1978
STD-Singer-1974-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1974
STD-Sun-2000-(Perp),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Not reported.,0621
STD-Tamminga-1994-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested.,1994
STD-Volavka-2002-(H),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] identical tablets[comma] untested.,2002
STD-Wang-2001-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,2001
STD-Wang-2006a-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2006b-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Not reported.,2006
STD-Xia-2002-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,2002
STD-Xu-1985-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Double blind[comma] untested; two independent raters gave the assessment; all tablets were indistinguishable in all aspects of their appearance.,1985
STD-Yang-1997-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,1997
STD-Yang-2002-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,2002
STD-Yang-2004-a-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,2004
STD-Zhang-1996-(CPZ),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,No details.,8366
STD-Zhang-2000-(Thi),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Not reported.,8405
STD-Zhang-2007-(Lox),Clozapine versus typical neuroleptic medication for schizophrenia,Unclear Risk,Not reported.,2007
STD-Bechdolf-2004,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Single - most assessments by independent raters not involved in treatment.,2004
STD-Buchkremer-1997,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,High risk,Data recorded by trained project staff who were not blind with respect to the group of allocation.,1997
STD-Cather-2005,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Rater blind to allocation.,2005
STD-Drury-2000,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,High risk,All participants were rated by first author with a subset rated blindly by two other authors.,1996
STD-Durham-2003,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Independent raters.,2003
STD-Garety-2008-a,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Primary outcome (relapse) was masked. 88% of secondary outcomes were completed masked (i.e. the allocation of the patient had not been revealed to the assessor).,2008
STD-Haddock-1999,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,At outcome - no further details.,1999
STD-Haddock-2009,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Masking maintained by ensuring therapists and assessors were housed in separate accommodation[comma] therapy files were kept separately from data and clinical staff was repeatedly instructed not to disclose any knowledge of therapy group to assessors.,2009
STD-Jackson-2008,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Single - raters blind to allocated treatment.,2008
STD-Kemp-1998,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,High risk,Blinding not reported.,1996
STD-Klingberg-2009,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to allocation.,2009
STD-Levine-1998,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters unaware of allocation.,1998
STD-Lewis-2002,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to treatment allocation.,2002
STD-Lewis-2002---Liverpool,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to treatment allocation.,2002
STD-Lewis-2002---Manchester,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to treatment allocation.,2002
STD-Lewis-2002---Nottingham,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to treatment allocation.,2002
STD-O'Donnell-2003,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,High risk,Raters blind to allocation.,2003
STD-Penn-2009,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to allocation.,2009
STD-Pinto-1999,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,High risk,No report of blinding raters to allocation.,1999
STD-Sensky-2000,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to treatment condition.,2000
STD-Tarrier-1999,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to treatment condition.,1999
STD-Turkington-2000,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to treatment condition.,2000
STD-Valmaggia-2005,Cognitive behavioural therapy versus other psychosocial treatments for schizophrenia,Low risk,Raters blind to allocation.,2005
STD-Medalia-1998,Cognitive rehabilitation for people with schizophrenia and related conditions,Information could not be retrieved,Information could not be retrieved,1998
STD-Tompkins-1995,Cognitive rehabilitation for people with schizophrenia and related conditions,Information could not be retrieved,Information could not be retrieved,1995
STD-Wykes-1999,Cognitive rehabilitation for people with schizophrenia and related conditions,Information could not be retrieved,Information could not be retrieved,1999
STD-Bauer-2006,Collaborative care approaches for people with severe mental illness,High risk,Participants   Quote: "Because participants could not be blinded to the intervention[comma] we could not guarantee blinding of the research assistants". (Bauer 2006a[comma] pg 932).  Comment: Participants were not blinded.  Personnel:  Quote: "The study chair and sites remained blind to outcome until follow-up was complete." (Bauer 2006b[comma] pg 939). Also[comma] see 'blinding of outcome assessment section below'.  Comment: Blinding of key study personnel attempted[comma] but likely that it could have been broken.,2006
STD-McCabe-2016,Communication skills training for mental health professionals working with people with severe mental illness,Unclear Risk,Participants were blinded for primary and secondary outcomes as they did not know whether the psychiatrists had undergone communication skills training or not. It was not possible to blind the psychiatrists involved in the study.,2014
STD-Burns-1993,Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality,Information could not be retrieved,Information could not be retrieved,1993
STD-Merson-1992,Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality,Information could not be retrieved,Information could not be retrieved,1992
STD-Tyrer-1998,Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality,Information could not be retrieved,Information could not be retrieved,1998
STD-O'Donnell-2003,Compliance therapy for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Burns-2013,Compulsory community and involuntary outpatient treatment for people with severe mental disorders,High risk,See above; randomisation involved allocation to 2 different types of legal status. Therefore[comma] it was impossible and unlawful to mask research assistants[comma] treating clinicians or participants.,2013
STD-Steadman-2001,Compulsory community and involuntary outpatient treatment for people with severe mental disorders,High risk,No specific mention in the study. Although self-report measures were used for at least some of the outcomes[comma] it was unlikely participants[comma] clinicians or assessors were blind to treatment status. There was also confusion that resulted in some control participants and their clinicians believing that they were in the intervention group.,2001
STD-Swartz-1999,Compulsory community and involuntary outpatient treatment for people with severe mental disorders,High risk,No specific mention in the study. Although self-report measures were used for at least some of the outcomes[comma] it is unlikely participants[comma] clinicians or assessors were blind to treatment status.,1999
STD-Fenton-1979,Crisis intervention for people with severe mental illnesses,Unclear Risk,Not described[comma] raters 'independent of treatment teams'.,1979
STD-Fenton-1998,Crisis intervention for people with severe mental illnesses,High risk,Not described[comma] but research interviewers collected some data from medical records[comma] therefore unlikely to be blinded.,1998
STD-Hoult-1983,Crisis intervention for people with severe mental illnesses,Unclear Risk,Not described.,1983
STD-Howard-2010,Crisis intervention for people with severe mental illnesses,High risk,Researchers collecting measures not blinded.,2010
STD-Johnson-2005,Crisis intervention for people with severe mental illnesses,High risk,Article states 'blinding of researchers[comma] clinicians or patients was not possible'.,2005
STD-Muijen-1992,Crisis intervention for people with severe mental illnesses,Unclear Risk,Not described.,1992
STD-Pasamanick-1964a,Crisis intervention for people with severe mental illnesses,Unclear Risk,Not described.,1964
STD-Stein-1975,Crisis intervention for people with severe mental illnesses,Unclear Risk,Not described.,1975
STD-Rohricht-2006,Dance therapy for schizophrenia,Unclear Risk,Single[comma] but not tested.,2006
STD-Creed-UK-1990,Day hospital versus admission for acute psychiatric disorders,High risk,Not blind.,1990
STD-Creed-UK-1996,Day hospital versus admission for acute psychiatric disorders,High risk,Not blind.,1996
STD-Dick-UK-1985,Day hospital versus admission for acute psychiatric disorders,High risk,Not blind.,1985
STD-Herz-US-1971,Day hospital versus admission for acute psychiatric disorders,High risk,Not blind.,1971
STD-Kallert-EU-2007,Day hospital versus admission for acute psychiatric disorders,High risk,Not blinded.,2007
STD-Kris-US-1965,Day hospital versus admission for acute psychiatric disorders,High risk,Not blind.,1965
STD-Schene-NL-1993,Day hospital versus admission for acute psychiatric disorders,High risk,Not blind.,1993
STD-Sledge-US-1996,Day hospital versus admission for acute psychiatric disorders,High risk,Not blind.,1996
STD-Wiersma-NL-1989,Day hospital versus admission for acute psychiatric disorders,High risk,Not blind.,1989
STD-Zwerling-US-1964,Day hospital versus admission for acute psychiatric disorders,High risk,Not blind.,1964
STD-Glick-1986,Day hospital versus outpatient care for people with schizophrenia,High risk,Not blinded by design.,1986
STD-Linn-1979,Day hospital versus outpatient care for people with schizophrenia,Low risk,Independent raters[comma] authors affirm that outcome data blinded.,1979
STD-Meltzoff-1966,Day hospital versus outpatient care for people with schizophrenia,Unclear Risk,Research personnel had no dealing with patients[comma] but patients were questioned about their day by their assessor.,1966
STD-Weldon-1979,Day hospital versus outpatient care for people with schizophrenia,High risk,Not blinded by design.,1979
STD-Angst-1973,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1973
STD-Bankier-1973,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1973
STD-Borger-1978,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1978
STD-Chouinard-1986,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1986
STD-Frangos-1978,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1978
STD-Galfi-1973,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1973
STD-Magnus-1979,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1979
STD-Malm-1974,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1974
STD-Russell-1982,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1982
STD-Tegeler-1979,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1979
STD-Vereecken-1972,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1972
STD-Villeneuve-1970,Depot fluspirilene for schizophrenia,Information could not be retrieved,Information could not be retrieved,1970
STD-Bechelli-1985,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1985
STD-Chouinard-1984,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1984
STD-Cookson-1986,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1986
STD-Eberhard-1986,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1986
STD-Eklund-1991,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1991
STD-Kissling-1985,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1985
STD-McKane-1987,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1987
STD-Wistedt-1984,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1984
STD-Wistedt-1991,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1991
STD-Zissis-1982,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1982
STD-Zuardi-1983,Depot haloperidol decanoate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1983
STD-Ahlfors-1980,Depot perphenazine decanoate and enanthate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1980
STD-Eufe-1979,Depot perphenazine decanoate and enanthate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1979
STD-Knudsen-1985c,Depot perphenazine decanoate and enanthate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1985
STD-Tegeler-1979,Depot perphenazine decanoate and enanthate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1979
STD-Albert-1980,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1980
STD-Bechelli-1985,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1985
STD-Bechelli-1986,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1986
STD-Chai-1998,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1998
STD-Chouinard-1978,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1978
STD-Dencker-1973,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1973
STD-Dencker-1978,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1978
STD-Jain-1975,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1975
STD-Leong-1989,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1989
STD-Robak-1973,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1973
STD-Schlosberg-1978,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1978
STD-Schneider-1981,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1981
STD-Simon-1978,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1978
STD-Singh-1979,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1979
STD-Steinert-1986,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1986
STD-Vereecken-1972,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1972
STD-Woggon-1977,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1977
STD-Yan-hua-1993,Depot pipotiazine palmitate and undecylenate for schizophrenia,Information could not be retrieved,Information could not be retrieved,1993
STD-Buccheri-1996,Distraction techniques for schizophrenia,Information could not be retrieved,Information could not be retrieved,1996
STD-Cole-1997,Distraction techniques for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Lamontagne-1983,Distraction techniques for schizophrenia,Information could not be retrieved,Information could not be retrieved,1983
STD-Medalia-2000,Distraction techniques for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Tarrier-1993,Distraction techniques for schizophrenia,Information could not be retrieved,Information could not be retrieved,1993
STD-Gutride-1973,Drama therapy for schizophrenia or schizophrenia-like illnesses,Information could not be retrieved,Information could not be retrieved,1973
STD-Nitsun-1974,Drama therapy for schizophrenia or schizophrenia-like illnesses,Information could not be retrieved,Information could not be retrieved,1974
STD-Qu-2000,Drama therapy for schizophrenia or schizophrenia-like illnesses,Information could not be retrieved,Information could not be retrieved,2000
STD-Whetstone-1986,Drama therapy for schizophrenia or schizophrenia-like illnesses,Information could not be retrieved,Information could not be retrieved,1986
STD-Zhou-2002,Drama therapy for schizophrenia or schizophrenia-like illnesses,Information could not be retrieved,Information could not be retrieved,2002
STD-Calver-2015,Droperidol for psychosis-induced aggression or agitation,Low risk,Quote: "The list of study codes with allocations was generated by a research assistant and supplied to the Calvary Mater Newcastle pharmacy[comma] so that the investigators and treating staff remained unaware of the allocations". Response: both participants and personnel were blind to the allocations.,2015
STD-Chan-2013,Droperidol for psychosis-induced aggression or agitation,Low risk,Quote: "All patients[comma] ED staff[comma] and study personnel remained blinded to group allocation until data entry and analyses were completed". Response: low risk of performance bias.,2013
STD-Cocchi-1971,Droperidol for psychosis-induced aggression or agitation,Unclear Risk,Study described as "double-blind"[comma] but external assessors and doctors involved in patient care discussed every case in order to get a global evaluation of them.,1971
STD-Knott-2006,Droperidol for psychosis-induced aggression or agitation,Unclear Risk,Quote: "patients and staff remained blinded to which drug was used throughout each patient’s stay". Response: blinding probably practiced.,2006
STD-Resnick-1984,Droperidol for psychosis-induced aggression or agitation,Low risk,Quote: "a double-blind clinical comparison of droperidol and haloperidol was undertaken". Response: personnel and participants were probably blind to the interventions.,1984
STD-Van-Leeuwen-1977,Droperidol for psychosis-induced aggression or agitation,Low risk,Quote: "the study was strictly double blinded..." Response: participants and personnel were probably blind to the intervention.,1977
STD-Alvarez-Spain,Early intervention for psychosis,High risk,Single.,2005
STD-Amminger-Austria,Early intervention for psychosis,Unclear Risk,Double blind[comma] untested.,2006
STD-Berger-Australia,Early intervention for psychosis,Unclear Risk,Double blind[comma] untested.,2004
STD-EDIE-UK,Early intervention for psychosis,High risk,Single blind.,2004
STD-Edwards-Australia,Early intervention for psychosis,High risk,Single blind.,2006
STD-EIPS-Germany,Early intervention for psychosis,High risk,Not stated.,2004
STD-Jackson-Australia,Early intervention for psychosis,High risk,Single[comma] untested.,2005
STD-Killackey-Australia,Early intervention for psychosis,Unclear Risk,Not reported.,2008
STD-Leavey-UK,Early intervention for psychosis,Low risk,Single[comma] untested.,2004
STD-LEO-CAT-UK,Early intervention for psychosis,High risk,Open study.,2004
STD-LifeSPAN-Australia,Early intervention for psychosis,High risk,Single blind.,1999
STD-Linszen-Amsterdam,Early intervention for psychosis,High risk,No details.,2001
STD-LIPS-Germany,Early intervention for psychosis,High risk,Open label.,2007
STD-OPUS-Scandinavia,Early intervention for psychosis,Low risk,Independent assessors aware of treatment allocation; 5-year follow-up assessors unaware of treatment allocation.,2000
STD-PACE-Australia,Early intervention for psychosis,High risk,Not blinded.,2002
STD-PRIME-USA,Early intervention for psychosis,Unclear Risk,Double blind[comma] untested.,2003
STD-Uzenoff-USA,Early intervention for psychosis,High risk,Not blinded.,2008
STD-Zhang-China,Early intervention for psychosis,High risk,Not reported.,1994
STD-Kelly-1992,Educational games for mental health professionals,Unclear Risk,Single (assessor)[comma] untested.,1992
STD-Abraham-1987,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1987
STD-Abrams-1967,Electroconvulsive therapy for schizophrenia,Unclear Risk,No details.,1967
STD-Agarwal-1985,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1985
STD-Bagadia-1981,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1981
STD-Bagadia-1988,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1988
STD-Baker-1958,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1958
STD-Baker-1960,Electroconvulsive therapy for schizophrenia,High risk,Not blinded.,1960
STD-Brandon-1985,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1985
STD-Brill-1959,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1959
STD-Chanpattana-1999a,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1999
STD-Chanpattana-2000,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,2000
STD-Doongaji-1973,Electroconvulsive therapy for schizophrenia,Unclear Risk,Single blind[comma] untested.,1973
STD-Girish-2003,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,2003
STD-Goswami-2001,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,2001
STD-Janakiramiah-1981,Electroconvulsive therapy for schizophrenia,Unclear Risk,Single blind[comma] untested.,1981
STD-Janakiramiah-1982,Electroconvulsive therapy for schizophrenia,High risk,Single blind[comma] untested.,1982
STD-May-1968,Electroconvulsive therapy for schizophrenia,Unclear Risk,Single blind[comma] untested.,1968
STD-Miller-1953,Electroconvulsive therapy for schizophrenia,High risk,Open.,1953
STD-Naidoo-1956,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1956
STD-Sarita-1998,Electroconvulsive therapy for schizophrenia,Unclear Risk,,1998
STD-Sarkar-1994,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1994
STD-Small-1982,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind (drugs) untested[comma] single blind (ECT).,1982
STD-Taylor-1980,Electroconvulsive therapy for schizophrenia,Unclear Risk,Mostly double blind[comma] untested.,1980
STD-Ukpong-2002,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,2002
STD-Ungvari-1982,Electroconvulsive therapy for schizophrenia,Unclear Risk,Double blind[comma] untested.,1982
STD-Wu-1989,Electroconvulsive therapy for schizophrenia,Unclear Risk,Single blind[comma] untested.,1989
STD-Glazer-1985,Estrogen for schizophrenia,Information could not be retrieved,Information could not be retrieved,1985
STD-Good-1999,Estrogen for schizophrenia,Information could not be retrieved,Information could not be retrieved,1999
STD-Kulkarni-1996,Estrogen for schizophrenia,Information could not be retrieved,Information could not be retrieved,1995
STD-Kulkarni-2001,Estrogen for schizophrenia,Information could not be retrieved,Information could not be retrieved,2001
STD-Louza-2004,Estrogen for schizophrenia,Information could not be retrieved,Information could not be retrieved,2004
STD-Beebe-2005,Exercise therapy for schizophrenia,Low risk,Single[comma] researcher blinded to group status[comma] untested.,2005
STD-Duraiswamy-2007,Exercise therapy for schizophrenia,Low risk,Single[comma] researcher blinded to group status[comma] untested.,2007
STD-Marzaloni-2008,Exercise therapy for schizophrenia,Unclear Risk,Single[comma] researcher blinded to group status[comma] untested.,2008
STD-Barber-1988*,Family intervention (brief) for schizophrenia,Unclear Risk,Not stated.,1988
STD-Shinde-2005,Family intervention (brief) for schizophrenia,High risk,Non-blinded.,2005
STD-Smith-1987,Family intervention (brief) for schizophrenia,Unclear Risk,Not stated.,1987
STD-Youssef-1987,Family intervention (brief) for schizophrenia,High risk,Quote: "subjects were approached by the investigator and informed verbally of the purpose of the study" (p613).,1987
STD-Barrowclough-2001,Family intervention for schizophrenia,High risk,Single[comma] untested.,2001
STD-Bloch-1995,Family intervention for schizophrenia,High risk,Not blinded.,1995
STD-Bradley-2006,Family intervention for schizophrenia,Unclear Risk,Single blind[comma] independent researchers who were blind to study condition[comma] untested.,2006
STD-Buchkremer-1995,Family intervention for schizophrenia,High risk,Not blinded.,1995
STD-Carra-2007,Family intervention for schizophrenia,Unclear Risk,Follow-up assessments were carried out by research assistants blind about the treatment assigned[comma] untested.,2007
STD-Chen-2005,Family intervention for schizophrenia,Unclear Risk,No details.,2005
STD-Chien-2004,Family intervention for schizophrenia,Unclear Risk,No reported.,2004
STD-Dai-2007,Family intervention for schizophrenia,Unclear Risk,No details.,2007
STD-De-Giacomo-1997,Family intervention for schizophrenia,High risk,Not blind.,1997
STD-Du-2005,Family intervention for schizophrenia,Unclear Risk,No details.,2005
STD-Dyck-2002,Family intervention for schizophrenia,High risk,Open study.,2002
STD-Falloon-1981,Family intervention for schizophrenia,High risk,Not blind.,1981
STD-Fernandez-1998,Family intervention for schizophrenia,High risk,Not blind.,1998
STD-Glynn-1992,Family intervention for schizophrenia,High risk,Not blind.,1992
STD-Goldstein-1978,Family intervention for schizophrenia,Unclear Risk,Single blind[comma] untested.,1978
STD-Gong-2007,Family intervention for schizophrenia,High risk,Open.,2007
STD-Guo-2007,Family intervention for schizophrenia,High risk,Open study.,2007
STD-Herz-2000,Family intervention for schizophrenia,High risk,Not blind.,2000
STD-Hogarty-1986,Family intervention for schizophrenia,High risk,Not blind.,1986
STD-Hogarty-1997,Family intervention for schizophrenia,High risk,No blind.,1997
STD-Leavey-2004,Family intervention for schizophrenia,Unclear Risk,Single blind[comma] untested.,2004
STD-Leff-1982,Family intervention for schizophrenia,High risk,Not blind.,1982
STD-Leff-1989,Family intervention for schizophrenia,Unclear Risk,Single[comma] untested.,1989
STD-Leff-2001,Family intervention for schizophrenia,Unclear Risk,Single blind[comma] untested.,2001
STD-Li-2004,Family intervention for schizophrenia,Unclear Risk,No details.,2004
STD-Li-2005a,Family intervention for schizophrenia,High risk,Open study.,2005
STD-Linszen-1996,Family intervention for schizophrenia,Unclear Risk,Single[comma] untested.,1996
STD-Liu-2003,Family intervention for schizophrenia,Unclear Risk,No details.,2003
STD-Liu-2007,Family intervention for schizophrenia,High risk,Open study.,2007
STD-Luping-2007,Family intervention for schizophrenia,Unclear Risk,No details.,2007
STD-Lv-2003,Family intervention for schizophrenia,Unclear Risk,No details.,8462
STD-Magliano-2006,Family intervention for schizophrenia,High risk,Open study.,2006
STD-Mak-1997,Family intervention for schizophrenia,High risk,Not blind.,1997
STD-McFarlane-1995,Family intervention for schizophrenia,Unclear Risk,Partial blinding[comma] untested.,1995
STD-Merinder-1999,Family intervention for schizophrenia,Unclear Risk,Single[comma] untested.,1999
STD-Posner-1992,Family intervention for schizophrenia,Unclear Risk,Not stated.,1992
STD-Qiu-2002,Family intervention for schizophrenia,Unclear Risk,Not reported.,8447
STD-Ran-2003,Family intervention for schizophrenia,Unclear Risk,Assessors blind[comma] no further details.,2001
STD-Randolph-1994,Family intervention for schizophrenia,Unclear Risk,Not stated.,1994
STD-Schooler-1997,Family intervention for schizophrenia,Unclear Risk,Not stated.,1989
STD-Shi-2000,Family intervention for schizophrenia,Unclear Risk,Not stated.,2000
STD-Szmukler-2003,Family intervention for schizophrenia,High risk,Not blinded.,2003
STD-Tan-2007,Family intervention for schizophrenia,High risk,Open study.,2007
STD-Tarrier-1988,Family intervention for schizophrenia,Unclear Risk,Single[comma] untested.,1988
STD-Vaughan-1992,Family intervention for schizophrenia,Unclear Risk,Single blind.,1992
STD-Wang-2006,Family intervention for schizophrenia,High risk,None.,2006
STD-Xiang-1994,Family intervention for schizophrenia,Unclear Risk,Double blind[comma] untested.,1994
STD-Xiang-2005,Family intervention for schizophrenia,High risk,Open study.,2005
STD-Xiong-1994,Family intervention for schizophrenia,Unclear Risk,Single blind[comma] untested.,1994
STD-Zhang-1994,Family intervention for schizophrenia,Unclear Risk,Single[comma] untested.,1994
STD-Zhang-2006a,Family intervention for schizophrenia,High risk,Open study.,2006
STD-Zhang-2006b,Family intervention for schizophrenia,Unclear Risk,No details.,2006
STD-Zhou-2007,Family intervention for schizophrenia,High risk,Open study.,2007
